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Background: Persistent human papillomavirus (HPV) infection is a well-known cause of 
cervical and anogenital cancers. In the past decade, oral HPV infection was established as 
a cause of oropharyngeal squamous cell carcinoma (OPSCC), but risk factors for oral 
HPV persistence are poorly understood. Increasing HPV-associated OPSCC has been 
reported in several Western countries, predominantly in younger white men. Trends in 
Asian populations have not been well-described, but may differ since the epidemiology 
of HPV-associated cancers varies by age, sex, geography and race/ethnicity. 
 
Objectives: We aimed to investigate potential factors associated with oral HPV 
persistence, including 1) serum cytokines, 2a) recreational drug use and 2b) medication 
use. We also explored: 3) the epidemiology of OPSCC and other potentially HPV-
associated cancers in Singapore, a Southeast Asian country. 
 
Methods: For aims 1 and 2, participants were enrolled in the “Persistence of Oral 
Papillomavirus Study” (POPS), a U.S.-based cohort study. Oral rinse samples were 
collected semi-annually for HPV DNA testing. Blood samples were collected for 
cytokine testing. Drug and medication use were assessed via questionnaire. For aim 3, the 
epidemiology of potentially HPV-associated cancers in Singapore was described, using 
cancer registry data. Data were analyzed using Wei-Lin-Weissfeld regression (aims 1&2) 







Results: From 2010 to 2014, 1,666 participants were enrolled in POPS. Oral HPV 
prevalence was 36% and median time to clearance was 6.3 months. Higher TNF-α 
concentration was associated with decreased oral HPV clearance in men (highest vs. 
lowest quartile, adjusted hazard ratio [aHR]=0.52, 95%CI=0.34-0.79) and women 
(aHR=0.76, 95%CI=0.55-1.04), p-interaction=0.049. Cocaine use (aHR=0.60, 
95%CI=0.41-0.88) and antipsychotic medication use (aHR=0.75, 95%CI=0.57-0.99) 
were also each associated with reduced clearance. In Singapore, OPSCC incidence 
increased in both genders (men 1993-2012, annual percentage change [APC]=1.9%, 
p<0.001; women 1968-2012, APC=2.0%, p=0.01), in contrast to non-oropharyngeal head 
and neck cancers. The incidence of HPV-associated cancers varied by ethnicity. 
 
Conclusions: Some immunomodulatory agents, including high serum TNF-α, cocaine, 
and antipsychotic medication may reduce oral HPV clearance. Similar to trends in other 
countries, OPSCC incidence increased in Singapore in recent years, suggesting the 
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Chapter 1. Introduction 
 
 
Human papillomavirus (HPV) is a common sexually transmitted infection and 
well-known cause of cervical and other anogenital cancers.
1
 In the past decade, oral 
infection with HPV was established as a causal factor for a subset of head and neck 
squamous cell carcinomas (HNSCC), particularly oropharyngeal squamous cell 
carcinoma (OPSCC).
2-7
 In the 1990s to early 2000s, an estimated 35-41% of OPSCC 
were attributed to HPV,
8,9
 and the proportion may now be as high as 80% in some 
industrialized countries.
10
 Similar to HPV infection at other anatomic sites, oral HPV 
infection is acquired through sexual contact,
11
 and the majority of infections clear in 1-2 
years with no clinically significant sequelae.
10,12
 However, persisting infection increases 
the risk for developing viral-associated malignant transformations and neoplasms.
11
 
Therefore, the continued presence of detectable oral HPV infection is considered a risk 
factor for the development of OPSCC.
13
  
Our understanding of oral HPV natural history, and factors that influence oral 
HPV clearance or persistence, is limited. Two longitudinal studies of oral HPV infection 
suggest that male sex, older age, smoking, lower CD4 T cell count, and the use and 
duration of highly active anti-retroviral therapy (HAART) are associated with reduced 
oral HPV clearance.
14,15
 Human immunodeficiency virus (HIV)-related 
immunosuppression has also been associated with reduced clearance, but it is not known 
whether other types of immune-modulation may have a similar effect or whether other 






the natural history of oral HPV has some similarities to that of cervical HPV, but there 
also appear to be some important differences.
14
 Risk factor characteristics of HPV-
associated HNSCC appear to differ from that of alcohol/tobacco-related HNSCC, which 
have been extensively documented.
3,16
 Therefore, additional research is needed to 
examine the unique natural history of oral HPV and to describe risk factors for persistent 
oral HPV infection.  
Epidemiologic and molecular data indicate that the proportion of OPSCC caused 
by HPV is increasing, predominantly among men, people of white race and younger birth 
cohorts.
17-20
 This trend has mainly been observed in more economically developed 
Western countries.
17,20
 From 1988 to 2004, the population-level incidence of HPV-related 
OPSCC in the U.S. increased by 225% (95% CI, 208% to 242%; from 0.8 per 100,000 to 
2.6 per 100,000),
2
 and between 2004 and 2008, nearly 3 times as many men (9,356 cases) 
as women (2,370 cases) were newly diagnosed each year.
21
 Worldwide, ~137,000 cases 
of OPSCC were diagnosed in 2008,
11
 with higher incidence in the U.S. and Europe as 
compared to some parts of Asia.
10
 Although the link between HPV and OPSCC is 
strongly supported by molecular and epidemiologic evidence, the reasons for differences 
in OPSCC incidence by sex, age and geography remain unclear.  
Increased knowledge on factors related to HPV persistence and population 










The objectives of this dissertation research were to: 
 
1. Investigate whether immunologic factors, as measured by cytokine expression, are 
associated with oral HPV clearance in a U.S.-based cohort study of HIV-infected and 
HIV-uninfected adults. (Chapter 3) 
 
2.Explore whether a) recreational drug use and b) medication use are associated with oral 
HPV clearance in a U.S.-based cohort study of HIV-infected and HIV-uninfected adults. 
(Chapters 4 and 5) 
 
3. Evaluate ethnic, age, and gender subgroups that may be at increased risk for 
oropharyngeal and other HPV-associated cancers in Singapore, a racially heterogeneous 
Asian city-state. Population-level trends in incidence are described using data from a 
nationally representative cancer registry. (Chapter 6) 
 








Chapter 2. Overview of HPV, head and neck squamous cell 
carcinomas and other HPV-associated cancers 
 
HPV is a small DNA virus that preferentially infects undifferentiated basal cells 
of skin and mucosal surfaces, including the lining of the anogenital tract and oral cavity.
22
 
Of the >150 HPV genotypes, >15 types have been associated with human cancers,
10
 and 
overall, HPV accounts for approximately 5% (600,000 cases) of cancers worldwide 
annually.
23
 HPV genotypes are subdivided into 2 categories: high-risk/oncogenic types 
and low-risk/non-oncogenic types, based on their carcinogenicity in humans.
10
 Common 
high-risk/oncogenic types include HPV-16, 18, 31, 33, 35, 45, 52 and 58, classified 
mostly based on evidence of their contribution to ~91% of cervical cancers.
11
 HPV16 
causes the majority of HPV-related cancers.
7
  
The pathobiology of oral HPV infection is thought to be similar to infection at 
cervical and other anatomic sites.
11
 The majority of HPV infections are asymptomatic 
and/or benign,
24
 with minimal/no viremia since infection and viral protein production are 
strictly confined to keratinocytes.
25
 T cell responses effectively resolve the majority of 
infections.
26
 In cases where HPV successfully evades immune clearance, E6/E7 
oncoprotein expression leads to excessive viral proliferation in infected lower and middle 
epithelial layers,
24
  which eventually spreads to surface layers and results in lesion 
development.
27
 Deficient DNA repair and accumulation of genetic damage from these 









Persistent infection with oncogenic HPV types is a necessary cause of all cervical 
cancers and causes the majority of anal cancers and oropharyngeal cancers.
7,13
 A high 
proportion (~50-80%) of OPSCC is attributed to oncogenic HPV type 16,
11
 possibly 
because immune responses clear HPV16 less efficiently than other HPV types.
12,28
 Other 
well-studied HPV types include HPV18, which accounts for a substantial proportion 
(20%) of cervical cancers
29
 but appears to play a small role (2.8%) in oropharyngeal 
cancer;
30
 and, HPV6 and HPV11 which cause genital warts but do not cause cancer.
11
 
Historically, the primary risk factors for HNSCC have been tobacco and alcohol 
use.
31
 Although smoking and drinking still account for the majority of HNSCC, a decline 
in tobacco use in the U.S. and other countries has revealed an increasing proportion of 
HNSCC, primarily OPSCC, that are independently associated with HPV.
10
 Consistent 
with this trend, OPSCC in the past decade have been more likely to be never/light/former 
smokers, than patients diagnosed in previous decades.
32
 Compared to patients with HPV-
unrelated OPSCC, patients with HPV-related OPSCC are more likely to be middle-aged 
white men, and have higher socioeconomic status and higher educational level.
10,23
  
Previous research on oral HPV natural history 
The data available on oral HPV natural history are limited and results from cohort 
studies have been varied. A longitudinal study of oral HPV infections in men in the U.S., 
Mexico and Brazil found that the median duration of incident infections was 6.9 months 
(95% CI=6.2-9.3) for any HPV type, 6.3 months (6.0–9.9) for oncogenic HPV, and 7.3 
months (6.0–not estimable) for HPV16.
12
 A study of sexually active heterosexual men 
found that 72% of prevalent infections of any type cleared within ~4 months.
33






Italy found that in 30 oral HPV-infected subjects with low (3%) HPV16 prevalence, only 
2 infections persisted for 6 months and complete clearance was observed within 1 year.
34
 
A Finnish prospective study of 331 women and 131 male spouses found that at 2 years 
after initial oral HPV detection, none of the women and few (5%) of the men had cleared 
the infection.
35
 At 6 years of follow-up in this same cohort, persisting infections were 
primarily HPV16 (76%), and after including additional infections detected during the 
additional 4 years of follow-up, mean time to clearance of HPV16 infections was 18.6 
months.
36
 At 7 years of follow-up, 71% of the men had cleared oral HPV with most of 
the persisting infections caused by HPV16 (mean time to clearance: 21.7 months).
37
  
Oral HPV infection and persistence in HIV-infected individuals 
Studying HPV persistence in the context of HIV infection is of particular interest 
since HIV-infected individuals have a 2-3 times higher odds of prevalent oral HPV 
infection, even after accounting for sexual risk factors, and are more likely to get OPSCC 
than HIV-uninfected individuals.
38,39
 In the general U.S. population, ~7% of people have 
oral HPV infection at any one time.
40
 In HIV-infected individuals, the prevalence is as 
high as 40%.
5,39,41
 It is not clear whether the higher prevalence is due to increased 
acquisition or longer duration of infection.  
In a study of HIV-infected men and women, 48% of prevalent infections and 28% 
of newly detected infections remained persistent for at least 18 months.
42
 A study of 
women with or at risk for HIV found that current smoking, older age, lower CD4 T cell 
counts, and the use and duration of HAART therapy were associated with increased risk 
for 6-month persistence of infection.
14






current smoking were associated with reduced clearance, while HAART use was not 
associated with clearance.
15
 It is possible that HIV-related immunosuppression, such as 
lower CD4 T cell counts, may attenuate immune responses to HPV, facilitating 
persistence.
14
 However, it is unclear whether HIV-related immunosuppression alone 
explains the higher prevalence of oral HPV in HIV-infected individuals, particularly 
since a decrease in oral HPV prevalence has not been observed in the post-HAART era.
43
 
It is also possible that other factors commonly associated with HIV such as drug use, 






Chapter 3. The association of serum cytokines with clearance or 
persistence of oral HPV infection 
 
Abstract 
Background: Initial studies suggest higher serum levels of some pro-inflammatory 
cytokines may be associated with decreased cervical human papillomavirus (HPV) 
clearance. However, the relationship of cytokines with oral HPV clearance has not been 
explored. 
 
Methods: From 2010 to 2014, oral rinse and serum samples were collected semi-
annually from 1,601 adults. Oral rinse samples were tested for HPV DNA using PCR. 
Based on oral HPV results, 931 serum samples were selected for cytokine evaluation to 
include a roughly equal number of prevalent (n=307), incident (n=313), and no oral HPV 
infections (n=311). Electrochemiluminescence multiplex assays were used to determine 
the concentrations of IL-6, IL-8, TNF-α, IFN-γ, IL-1β, IL-2, IL-4, IL-10, IL-12 and IL-
13. The relationship between serum cytokine concentrations (categorized into quartiles) 
and oral HPV clearance was evaluated with Wei-Lin-Weissfeld regression models, 
adjusting for HPV infection type (prevalent vs. incident), age, HIV status, and CD4 T cell 
count. 
 
Results: Higher TNF-α concentration was associated with decreased clearance in men 






women (aHR=0.76, 95% confidence interval [CI]=0.55-1.04), with stronger associations 
in men than women (p-interaction=0.049). Higher IL-2 concentration was associated with 
reduced clearance in men (aHR=0.69, 95% CI=0.50-0.95), but not women (p-
interaction=0.058). Results were similar within CD4 T cell strata (CD4 ≥500 or 
CD4<500 cells/l) among HIV-infected participants. No other cytokines were associated 
with clearance.  
 








Background and rationale 
Oral infection with human papillomavirus (HPV) is an established causal factor 
for oropharyngeal squamous cell carcinoma (OPSCC).
19
 In the U.S., approximately 70% 
of OPSCC is caused by HPV, with higher incidence among men <60 years old and 
individuals with human immunodeficiency virus (HIV) infection.
19,39,44,45
 Similar to HPV 
infection at other anatomic sites, most oral HPV infections clear in 1-2 years.
1
 However, 
some individuals have persistently detected oral HPV infection, which is believed to be 
the precursor to HPV-related OPSCC.
13
 Understanding key immune differences in 
individuals with persistent oral HPV may help explain the disproportionate burden of 
HPV-related OPSCC in population subgroups. 
While the role of host immunity in oral HPV infection has not been explored, 
studies of cervical HPV infection have established that cell-mediated T cell responses are 
critical for viral clearance and lesion regression.
26,46
 Attempts to characterize these 
responses have found that women with persistent cervical HPV have distinct systemic 
and/or local cytokine profiles as compared to women who clear HPV or women without 
HPV infection.
47-51
 In particular, higher circulating or local levels of interleukin (IL)-6, 
IL-8 and tumor necrosis factor-alpha (TNF-α) have been associated with reduced cervical 
HPV clearance,
47-49
 suggesting that cytokines secreted may be predictive of disease 
progression and outcome, although results have been mixed.
52,53
 The relationships 
between cytokines and oral HPV infection, and any differences by biologic sex, have not 
been described. However, men have been noted to have a reduced inflammatory response 








Given that innate and acquired immune responses effectively resolve most HPV 
infections, persistent oral infection may reflect disruption or alteration of host anti-viral 
or inflammatory responses.
29,55
 Alternatively, immunologic differences between 
individuals may influence oral HPV clearance. For example, women with persistent 
cervical HPV infection have reduced lymphoproliferative responses to HPV16.
56
 HIV 
infection may further impact immune response, as HIV can alter cytokine secretion 
patterns, resulting in elevated circulating levels of pro-inflammatory cytokines such as 
IL-1, IL-6 and TNF-.
43,57-62
 Furthermore, pro-inflammatory cytokines can modulate 
HPV transcription, suggesting that HIV-related immune perturbations at the systemic 
level could affect oral infection.
43
  
 Since there is no standardized oral screening, or easily identifiable precursor 
lesion for OPSCC,
63,64
 reliably detectable biomarkers related to infection duration may 
help identify oral HPV-infected individuals at increased risk for persistent infection 
and/or HPV-related OPSCC. Current technology allows simultaneous measurement of 
multiple immune markers in a single sample using a multiplex format. Characterizing the 
serum cytokine profiles associated with oral HPV clearance may provide insight on 
immune cofactors relevant to oral HPV infection and identify important biomarkers for 
future research. The goals of this study were to evaluate whether select serum cytokines 
associated with inflammation may be related to oral HPV clearance and to explore 
differences by sex and degree of HIV-related immunosuppression as measured by CD4 T 








Study population  
From 2010 to 2014, 1,601 participants were enrolled in the “Persistence of Oral 
Papillomavirus Study” (POPS), a longitudinal cohort for studying oral HPV natural 
history. POPS was nested within two ongoing observational studies of men and women 
with or at risk for HIV: the Multicenter AIDS Cohort Study (MACS) and the Women’s 
Interagency HIV Study (WIHS). POPS participants were enrolled at 5 study centers: 
Baltimore (MACS), Pittsburgh (MACS), Brooklyn (WIHS), Bronx (WIHS), and Chicago 
(MACS and WIHS).
65-67
 Each study center’s Institutional Review Board approved the 
study. All participants provided written informed consent.  
 
Data collection 
At each semi-annual study visit, a 30-second Scope
®
 oral rinse and gargle sample 
was collected and tested for 37 types of HPV DNA. A blood sample was also obtained, 
from which HIV status, CD4 T cell count, and cytokine profile were determined. Data on 
behavioral cofactors were collected by survey. Surveys were administered via Computer-
assisted Self-interviewing (CASI) in the MACS and were interview-administered in the 
WIHS.  
 
Oral HPV detection and genotyping 
DNA was extracted from oral exfoliated cells using the Puregene DNA isolation 
kit (Gentra Systems, Minneapolis, MN). Extracted DNA samples were tested for HPV 






genome using PGMY primers.
68
 HPV-positive samples were genotyped using reverse 
line-blot hybridization (Roche Molecular Systems, Pleasanton, CA).
68
 Each sample was 
evaluated for the presence of high-risk/oncogenic types (16, 18, 31, 33, 35, 39, 45, 51, 52, 
56, 58, 59, 66) and low-risk/non-oncogenic types (6, 11, 26, 38, 40, 42, 53, 54, 55, 61, 
62, 64, 67, 68, 69, 70, 71, 72, 73, 81, 83, 84, 89, IS39), classified according to criteria 
from the International Agency for Research on Cancer.
7,69,70
 Participants with any of 
these HPV types were considered HPV-infected.  
Prevalent oral infections were defined as any type-specific oral HPV infection 
detected at study enrollment. For the purposes of this study, incident infections were 
defined as those preceded by at least one HPV-negative oral rinse, although it is possible 
some of these were re-expressed latent infections. Previous studies of oral HPV natural 
history have reported intermittent detection of oral HPV (i.e. HPV 
positive/negative/positive), although it is unclear whether this is due to reactivation of 
latent infection, newly-acquired infection, fluctuations in HPV viral load over time or 
assay limitations.
34,36,42
 In order to reduce misclassification bias, re-infection(s) with the 
same HPV type after clearance was not included in the analysis.  
Clearance was defined as two consecutive HPV-negative oral rinses, with time of 
clearance as the visit of the first negative oral rinse sample. A secondary less 
conservative definition of clearance was considered, requiring only one HPV-negative 
oral rinse sample. The duration of infection was defined as elapsed time from oral HPV 








Selection of serum samples for cytokine testing 
We selected 931 serum samples for cytokine evaluation. Serum samples were 
selected based on oral rinse HPV results in order to include a roughly equal number of 
prevalent (n=307), incident (n=313), and no oral HPV infections (n=311). We included 
all prevalent HPV samples, a random selection of incident HPV samples (55% of all 
incident HPV samples), and a comparison group of samples with no oral HPV DNA at 
study enrollment, frequency matched to samples with prevalent HPV by study 
participant’s HIV status and biologic sex. All of the serum samples selected for cytokine 
testing were from participants who contributed at least 3 oral rinses overall and at least 2 
oral rinses after incident oral HPV detection.  
Cytokines were evaluated using serum samples collected at the visit of incident 
HPV detection, or at study enrollment for participants with prevalent or no HPV 
infections. Some participants had prevalent infection at study enrollment and subsequent 
incident HPV that was also included in the study sample. For these cases, cytokines were 
determined separately in the serum sample corresponding to first detection of prevalent 
HPV and in the sample corresponding to incident HPV. Therefore, the 620 prevalent and 
incident serum samples selected for cytokine evaluation were obtained from 459 HPV-
infected participants.  
 
Serum cytokine testing  
Serum cytokines were determined using the MSD V-PLEX Human 






consists of the following: TNF-α, IL-6, IL-8, IFN-γ, IL-1, IL-2, IL-4, IL-10, IL-12 and 
IL-13. Cytokine testing was analyzed using the MSD 2400 Sector Imager using a 
standard protocol. The multiplex cytokine assay was previously validated and found to 




To confirm acceptable assay performance, 10% of the samples were tested in 
duplicate and coefficients of variation (CV) were calculated for each duplicate test. 
Duplicated cytokine results were considered acceptable if CV≤20%. Analysis was 
restricted to the cytokines that could be reliably detected in ≥60% of the samples tested: 
TNF-α, IL-6, IL-8, IFN-γ, IL-2 and IL-10. The other cytokines tested (IL-1, IL-4, IL-12 
and IL-13) were excluded from the analysis because >40% of samples had cytokine 
concentrations below the lowest detectable limit (Table 3-2).  
 
Statistical analyses 
Demographic and health characteristics of men and women in the study were 
compared using χ
2 
tests. Median cytokine concentrations were compared in serum 
samples that had prevalent, incident and no oral HPV DNA using a nonparametric test for 
trends across ordered groups.  
The analysis included 917 type-specific oral HPV infections from 620 samples 
among 459 participants (some participants were infected with multiple HPV types at the 
same visit and the cytokine values at that visit were applied to clearance analysis of all of 
those infections). Concentrations of each cytokine were categorized into quartiles (see 






quartiles based on sex-specific cytokine distributions and continuous cytokine 
concentrations (i.e. the per natural log increase in cytokine concentration), with similar 
results. 
Predictors of type-specific oral HPV clearance were explored using Wei-Lin-
Weissfeld (WLW) regression models, accounting for within-participant clustering of 
HPV infections.
72
 The effect of each cytokine was modeled separately in unadjusted 
models, and then in multivariable models adjusting for prevalent vs. incident infection 
type, age, HIV status, and CD4 T cell count at time of oral HPV detection, based on prior 
evidence that these factors are associated with oral HPV clearance. Stata 12 statistical 
software package was used for statistical analyses.
73
 Statistical significance was defined 
by a two-sided p-value <0.05.  
 
Results 
Characteristics of study participants are described in Table 3-1. Among the 766 
participants, half were men (52%) and the median age was 50 years. Approximately 74% 
of participants were HIV-infected, and 82% of these reported current use of antiretroviral 
therapy (ART). Compared to men, women were younger, more likely to be Black, HIV-
infected, and current smokers (p-values<0.05, Table 3-1).  Among HIV-infected 
participants, women had higher current HIV RNA viral load (p<0.0001), but similar CD4 
T cell count, as compared to men (p=0.17). 
Median follow-up time for infections was 16.7 months (interquartile range, IQR: 






longer time to clearance for prevalent infections (11.7 months; IQR 6.0-21.6) than 
incident infections (6.2 months; IQR 5.9-11.9).  
 
Comparison of serum cytokine concentrations by HPV status  
 Median serum concentrations of TNF-α, IL-8, IFN-γ, IL-10 and IL-2 increased by 
HPV infection status (each p-trend<0.05, Table 3-3). The lowest median concentrations 
of each of these cytokines were in samples from participants with no oral HPV infection, 
followed by samples from participants with incident HPV, and the highest concentrations 
were in samples from participants with prevalent HPV. When comparing samples with 
any oral HPV infection (prevalent or incident) to samples without oral HPV infection, the 
median serum concentrations of TNF-α, IL-8, IFN-γ, IL-10 and IL-2 were significantly 
higher (each p<0.05) in samples from HPV-infected participants (Table 3-4).  
 
Association of cytokines with oral HPV clearance 
Of the cytokines included in the analysis, TNF-α was most strongly associated 
with oral HPV clearance (Table 3-5). In unadjusted analyses, the highest quartile of TNF-
α was significantly associated with reduced oral HPV clearance in both men (HR=0.50, 
95% CI=0.35-0.72) and women (HR=0.67, 95% CI=0.48-0.94), as compared to the 
lowest TNF-α quartile (p-interaction=0.24). The second and third quartiles of TNF-α 
concentration were also associated with reduced oral HPV clearance in men but not in 
women (each p-interaction<0.05, Table 3-5). 
In unadjusted analyses, the highest quartile of IL-2 concentration was associated 






0.96), but not among women (HR=1.10, 95% CI=0.80-1.50), p-interaction=0.047. This 
finding should be interpreted with caution as IL-2 had the most values (35%) below the 
lower limit of detection, of all the cytokines included in the analysis. IL-6, IL-8, IFN-γ, 
and IL-10 concentration were not strongly associated with oral HPV clearance; marginal 
associations were observed in single quartiles for some of these cytokines in unadjusted 
analyses (Table 3-5), but none remained significant predictors of oral HPV clearance in 
adjusted analyses (results not shown). 
After adjusting for the effects of HPV infection type (prevalent vs. incident), age, 
HIV status and CD4 T cell count in a multivariable model, serum TNF-α concentration 
remained significantly associated with reduced oral HPV clearance in all quartiles for 
men (each p<0.01) and remained marginally associated with reduced clearance in the 
highest quartile for women (p-interaction=0.049, Table 3-6). IL-2 also remained 
associated with decreased oral HPV clearance in all quartiles in men only (each p<0.05). 
The associations of higher TNF-α and IL-2 concentrations on oral HPV clearance were 
stronger in men than women (TNF-α, p-interaction=0.049; IL-2, p-interaction=0.058).  
Results were similar when restricted to HIV-infected participants with baseline 
CD4 ≥500 or CD4<500 cells/l (results not shown) and when evaluating TNF-α and IL-2 
concentrations as continuous variables instead of quartiles (Table 3-7). When restricted to 
oncogenic HPV types, higher TNF- remained associated with reduced clearance in men, 
but not in women although interaction by oncogenic type was not statistically significant 
(p-interactions, men=0.96; women=0.29). When using sex-specific cytokine quartile 
cutoffs, results were also similar but the highest TNF-α quartile in women remained 






When using a less strict clearance definition of 1 HPV-negative oral rinse, similar 
patterns were observed, but associations were attenuated (data not shown).  
 
Discussion 
 We found that while most cytokines were not associated with oral HPV clearance, 
the highest serum TNF-α concentration quartile in our study population (4.94-19.33 
pg/ml) was associated with decreased oral HPV clearance in both sexes, with stronger 
associations in men than women. IL-2 concentration above the first quartile (0.21 
pg/ml) was associated with reduced oral HPV clearance in men only. These results 
suggest that higher levels of some inflammatory cytokines may decrease oral HPV 
clearance. 
 Our finding that higher TNF-α was associated with reduced oral HPV clearance is 
consistent with previous studies of cervical HPV, which found that women with 
persistent cervical HPV have higher serum TNF-α at their final study visit, as compared 
to women who cleared infection.
47,48
 In addition, our results show that higher serum 
TNF-α at first detection of oral HPV infection was associated with longer time to 
clearance, suggesting that TNF-α may be a relevant marker in early stages of oral HPV 
infection, in addition to being a marker of long-term infection. Furthermore, while 
previous studies restricted the study population to HIV-uninfected participants,
47-49,52
 the 
association between TNF- and clearance in our study remained similar after adjusting 
for HIV infection and CD4 T cell count, suggesting that the relationship between TNF-α 






TNF- plays an important role in inflammatory reactions and viral clearance. 
Since HPV infection of epithelial cells is sequestered from systemic immunity, and 
typically does not cause a highly inflammatory immune response,
74,75
 the reason why 
higher concentrations of TNF-α are associated with reduced clearance remains unclear. It 
is possible that these participants had higher systemic TNF- resulting from other pro-
inflammatory co-factors, such as concurrent illness or chronic conditions, which may 
promote or facilitate HPV persistence. Previous research suggests that although initial 
HPV infection does not cause an inflammatory reaction,
74,75
 persisting infection can 
activate inflammatory pathways, including ones with established roles in cancer 
promotion.
76
 Repeated longitudinal cytokine measurements, or cytokine measurements 
taken directly from the oropharynx, may show a decrease in TNF-α following HPV 
clearance, and may help clarify temporal patterns of immune response over the course of 
oral HPV infection.  
Some sex differences in the association of cytokines with oral HPV clearance 
were observed in this study. Genetic or hormonal differences that influence immune 
responses and HPV infection may explain the difference between men and women in 
strength of association of TNF-α and IL-2 with reduced clearance. Sex differences in 
cellular and humoral immune responses, as well as cytokine activity, have been 
consistently documented in previous research.
54,77,78
 Given that our study population was 
primarily middle-aged, it is also possible that hormonal changes related to oral 
contraceptive use and menopause in women might influence immune responses.
79,80
  
 Previous clinical studies have not found evidence that serum IL-2 may be related 






when stimulated with HPV E6/E7 oncoproteins in culture supernatants of peripheral 
blood mononuclear cells found that IL-2 responsiveness was strongly associated with 
cervical HPV16 persistence.
81
 Other studies have shown that plasma IL-2 levels can 
differ depending on cervical HPV positivity and/or disease stage, although results have 
varied.
51
 Our finding that IL-2 is related to decreased clearance in men may have been 
affected by its lower detectability, and may not represent true sex differences in IL-2. 
Therefore, the association of IL-2 with oral HPV clearance observed in this study 
warrants confirmation from other studies. 
 In contrast to previous studies on cervical HPV,
47-49
 IL-6 and IL-8 were not 
strongly associated with oral HPV clearance in this study. It is possible that these 
cytokines were expressed at time points not captured by the testing schedules, that 
concentrations differed between studies or that they may be involved in oral HPV 
clearance, but not at concentrations detectable in serum. Two previous analyses, which 
reported associations between IL-8 and reduced cervical HPV clearance were conducted 
in a weighted subpopulation of women with type-specific HPV infection persistently 
detected over a 9-year interval.
47,48
 Therefore, it is possible that IL-8 is associated with 
HPV infection at a later stage, or may be more relevant for established infections. We 
found that the concentrations of nearly all cytokines were indeed different across 
participants by HPV infection status, suggesting a linkage between cytokine profile and 
presence or duration of HPV infection. While the current analysis controlled for incident 
vs. prevalent infection type, longitudinal repeated measurements may be more 






 Our study had several strengths, including: enrollment of a large study population 
with high oral HPV prevalence, including men and women at multiple U.S. study sites; 
racial and ethnic diversity; inclusion of HIV-infected and HIV-uninfected participants; 
ability to control for biological and behavioral risk factors; evaluation of oral HPV 
infection in a prospective manner; and, centralized testing of cytokines using a validated 
multiplex assay. This study also had several limitations. Cytokine levels were only 
measured in serum, not saliva, although results of a recent study indicate that serum 
cytokine measurement may reflect markers detectable in oral samples.
82
 It remains 
uncertain how cytokine concentrations in the periphery may be related to viral clearance 
at the local site of infection, or how clearance may be affected by the contributing effects 
of the mucosal immunologic environment. Cytokines were measured at the time of first 
oral HPV detection so subsequent changes in cytokine concentration during infection 
could not be evaluated. Finally, the 6-month study visit intervals limited our ability to 




 To our knowledge, this is the first study to explore the association of circulating 
immune markers with oral HPV clearance. While the majority of cytokines were not 
related to oral HPV clearance, these results suggest higher TNF-α concentration may be 
associated with reduced clearance of oral HPV infection, and that the strength of 






longitudinal cytokine evaluation, are needed to clarify the role of TNF-α in oral HPV 
natural history.  
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Table 3-1. Description of study participant characteristics at baseline, overall and by sex
1
 









Infection type     0.88 
Incident only 152 (19.8) 77 (19.2) 75 (20.6)  
Any prevalent 307 (40.1) 163 (40.5) 144 (39.6)  
None 307 (40.1) 162 (40.3) 145 (39.8)  
Age (years)    <0.0001 
<45 200 (26.1) 58 (14.5) 142 (39.0)  
45-54 328 (42.9) 171 (42.6) 157 (43.1)  
≥55 238 (31.1) 173 (43.0) 65 (17.9)  
Race/Ethnicity    <0.0001 
White, non-Hispanic 254 (33.2) 238 (59.2) 16 (4.4)  
Black, non-Hispanic 413 (53.9) 144 (35.8) 269 (73.9)  
Other race or Hispanic  99 (12.9) 20 (5.0) 79 (21.7)  
Study site     
Baltimore, Maryland 140 (18.3) 140 (34.8) NA  
Bronx, New York 116 (15.1) NA 116 (31.9)  
Brooklyn, New York 134 (17.5) NA 134 (36.8)  
Chicago, Illinois 253 (33.0) 139 (34.6) 114 (31.3)  
Pittsburgh, Pennsylvania 123 (16.1) 123 (30.6) NA  
HIV status    0.02 
Uninfected 197 (25.7) 117 (29.1) 80 (22.0)  
Infected 569 (74.3) 285 (70.9) 284 (78.0)  
Current CD4 T cell count (cells/µL)    0.17 
≥500 313 (55.0) 165 (57.9) 148 (52.1)  
<500 256 (45.0) 120 (42.1) 136 (47.9)  
Current HIV RNA viral load 
(copies/mL) 
 
  <0.0001 
<200 415 (73.3) 228 (80.9) 187 (66.5)  
200-19,999 94 (16.7) 32 (11.3) 62 (22.1)  
≥20,000 54 (9.6) 22 (7.8) 32 (11.4)  
Current ART use    0.43 
No 101 (17.8) 47 (16.5) 54 (19.0)  
Yes 468 (82.2) 238 (83.5) 230 (81.0)  
Smoked cigarettes in the last 6 
months 
 
  <0.0001 
No 439 (57.8) 271 (68.3) 168 (46.3)  







For HPV-uninfected participants and participants with prevalent HPV, baseline was defined as POPS 






Table 3-2. Detectability of cytokines in 931 samples measured using 
electrochemiluminescence multiplex assays 
 














The lower limit of detection was defined as the lowest reliably detected standard. The upper limit of 
detection was specified by the manufacturer (Meso Scale Discovery -MSD Gaithersburg, MD). The 
detectability of the main cytokines of interest was not affected by HIV status, sex, incident/prevalent 






Table 3-3. Comparison of baseline serum cytokine concentrations (pg/ml) in 931 samples, by oral HPV status
1
 
 Median serum concentration at baseline (IQR)  
Cytokine 
No Oral HPV 
n=311 
Incident Oral HPV 
n=313 
Prevalent Oral HPV 
n=307 
p-trend 
TNF-α    3.1   (2.4-4.3)   3.3   (2.5-4.5)    3.5   (2.6-4.8) 0.009 
IL-6   1.0   (0.7-1.8)   1.1   (0.7-1.7)    1.1   (0.7-1.7) 0.41 
IL-8 15.2   (10.7-38.1) 16.4   (11.4-37.5)  19.5  (13.0-62.3) 0.001 
IFN-γ   8.0   (5.2-14.1)   8.2   (5.4-15.7)    9.4   (5.7-16.5) 0.03 
IL-10 0.47   (0.27-0.76)       0.55   (0.32-0.89)  0.60   (0.37-0.94) 0.001 
IL-2 0.27   (0-0.55) 0.34   (0-0.55)  0.38   (0-0.59) 0.007 
 
1
 For samples with no oral HPV or prevalent HPV, baseline was defined as POPS enrollment. For samples with incident HPV, baseline was defined as visit of 
incident HPV detection. Unadjusted (no log transformation) median cytokine concentrations and interquartile ranges (IQR, 25th to 75th percentiles, in 
parentheses) are shown. Bolding indicates values with p<0.05 in tests for trend.  Results were similar when restricted to only HIV-infected, or only HIV-

















 Median serum concentration at baseline (IQR)  
Cytokine 
No Oral HPV 
n = 311 
Oral HPV-infected  
n=620 
p-value 
TNF- 3.1   (2.4-4.3) 3.4  (2.5-4.7) 0.02 
IL-6 1.0   (0.7-1.8) 1.1  (0.7-1.7) 0.6 
IL-8 15.2  (10.7-38.1) 17.6  (12.0-46.7) 0.02 
IFN- 8.0  (5.2-14.1) 8.9  (5.5-16.1) 0.03 
IL-10 0.5  (0.3-0.8) 0.6  (0.3-0.9) 0.002 
IL-2 0.3  (0.0-0.5) 0.4  (0.0-0.6) 0.04 
 
1
 For samples with no oral HPV, baseline was defined as POPS enrollment. For samples with HPV, baseline was defined as visit of HPV detection. Unadjusted 
(no log transformation) median cytokine concentrations and interquartile ranges (IQR, 25th to 75th percentiles, in parentheses) are shown. Bolding indicates 






Table 3-5. Unadjusted association of cytokine concentration (by quartile) with oral HPV clearance among 459 participants with 917 
oral HPV infections, by sex
1
 
 Hazard ratio (95% CI) 
 Infections in Men, n=472 Infections in Women, n=445 
Cytokine Quartile 2 Quartile 3 Quartile 4 Quartile 2 Quartile 3 Quartile 4 
TNF-α 0.55 (0.40-0.76) 0.56 (0.40-0.78) 0.50 (0.35-0.72) 0.93 (0.67-1.30) 0.97 (0.68-1.39) 0.67 (0.48-0.94) 
IL-6 0.72 (0.53-0.99) 0.71 (0.49-1.02) 0.83 (0.61-1.12) 1.41 (0.97-2.05) 1.04 (0.71-1.52) 1.05 (0.71-1.54) 
IL-8 0.88 (0.64-1.20) 0.74 (0.51-1.07) 1.05 (0.75-1.48) 0.83 (0.58-1.20) 0.95 (0.71-1.29) 0.73 (0.53-1.00) 
IFN-γ 0.97 (0.70-1.34) 0.98 (0.69-1.40) 0.79 (0.53-1.17) 0.79 (0.54-1.14) 0.86 (0.63-1.17) 0.84 (0.61-1.16) 
IL-10 0.78 (0.58-1.06) 0.81 (0.58-1.14) 0.82 (0.58-1.15) 0.89 (0.63-1.24) 0.88 (0.61-1.25) 0.74 (0.55-1.00) 
IL-2 0.63 (0.42-0.93) 0.73 (0.54-1.00) 0.69 (0.50-0.96) 0.80 (0.52-1.22) 0.98 (0.71-1.36) 1.10 (0.80-1.50) 
  
1 







Table 3-6. Multivariable risk factors for oral HPV clearance among 459 participants with 917 oral HPV infections, by sex
1
 
Characteristic at visit of first oral HPV 
detection 












aHR (95% CI) 
TNF-α concentration (pg/ml)
2           
Quartile 1  115 2,557 Ref 59 1,443 Ref 
Quartile 2 77 3,593 0.56 (0.40-0.79) 69 1,869 0.97 (0.70-1.34) 
Quartile 3 62 2,713 0.60 (0.44-0.82) 84 2,392 1.07 (0.76-1.49) 
Quartile 4 46 2,432 0.52 (0.34-0.79) 81 3,264 0.76 (0.55-1.04) 
 p-interaction=0.049 
IL-2 concentration (pg/ml)
3           
Quartile 1 124 3,612 Ref 101 3,053 Ref 
Quartile 2 39 1,868 0.66 (0.45-0.96) 33 1,243 0.90 (0.58-1.37) 
Quartile 3 69 2,703 0.70 (0.52-0.93) 79 2,442 1.09 (0.82-1.47) 
Quartile 4 65 2,906 0.69 (0.50-0.95) 79 2,223 1.15 (0.85-1.57) 
 p-interaction=0.058 
Infection type            
Incident 140 2,908 Ref 148 2,480 Ref 
Prevalent 160 8,388 0.52 (0.40-0.67) 146 6,494 0.45 (0.34-0.59) 
Age (years)            
<45 63 1,995 Ref 107 2,929 Ref 
45-54 124 4,423 0.83 (0.61-1.12) 137 4,036 0.95 (0.74-1.22) 
≥55 113 4,877 0.67 (0.48-0.92) 50 2,009 0.82 (0.58-1.15) 
HIV and current CD4 cell count 
(cells/µL) 






HIV uninfected 74 2,326 Ref 53 1,370 Ref 
HIV infected, CD4≥500 124 4,386 0.89 (0.66-1.21) 93 3,157 0.78 (0.56-1.08) 
HIV infected, CD4<500 102 4,584 0.87 (0.64-1.19) 148 4,447 0.92 (0.68-1.25) 
 
1
 TNF-α and IL-2 were each analyzed in separate multivariable models adjusting for infection type, age, and HIV status/CD4 count. Covariates shown are from 
the model with TNF-α. Bolding indicates adjusted hazard ratios (aHR) with p<0.05.  
2 
TNF-α quartiles: 0.0-2.56 (Q1), 2.57-3.58 (Q2), 3.59-4.93 (Q3), 4.94-19.33 (Q4).  
3 









Table 3-7. Multivariable risk factors for oral HPV clearance with continuous cytokine values, by sex 
Characteristic at visit of first oral HPV 
detection 












aHR (95% CI) 
Ln TNF-α concentration (pg/ml)
1
 300 11,272 0.58 (0.40-0.85) 293 8,969 0.87 (0.72-1.05) 
 p-interaction=0.045 
Ln IL-2 concentration (pg/ml)
1
 297 11,066 0.86 (0.75-0.98) 292 8,963 1.01 (0.90-1.13) 
 p-interaction=0.067 
Infection type            
Incident 140 2,908 Ref 148 2,480 Ref 
Prevalent 160 8,388 0.51 (0.39-0.66) 146 6,494 0.45 (0.34-0.59) 
Age (years)            
<45 63 1,995 Ref 107 2,929 Ref 
45-54 124 4,423 0.83 (0.62-1.12) 137 4,036 0.95 (0.74-1.21) 
≥55 113 4,877 0.70 (0.51-0.95) 50 2,009 0.80 (0.56-1.13) 
HIV and current CD4 cell count (cells/µL)            
HIV uninfected 74 2,326 Ref 53 1,370 Ref 
HIV infected, CD4≥500 124 4,386 0.90 (0.67-1.21) 93 3,157 0.79 (0.57-1.11) 
HIV infected, CD4<500 102 4,584 0.85 (0.62-1.15) 148 4,447 0.91 (0.66-1.24) 
 
1
 TNF-α and IL-2 concentrations were natural log transformed. For log transformation, values of 0 were considered to be half the lower limit of detection. TNF-α 
and IL-2 were each analyzed in separate multivariable models adjusting for infection type, age, and HIV status/CD4 count. Covariates shown are from the model 







Table 3-8. Multivariable risk factors for oral HPV clearance with sex-specific cytokine quartiles, by sex
1
 
Characteristic at visit of first oral HPV 
detection 












aHR (95% CI) 
TNF-α concentration (pg/ml)
2       
  
  
Quartile 1  115 2,557 Ref 59 1,443 Ref 
Quartile 2 77 3,593 0.55 (0.39-0.78) 69 1,869 0.86 (0.63-1.17) 
Quartile 3 62 2,713 0.59 (0.42-0.82) 84 2,392 0.95 (0.66-1.35) 
Quartile 4 46 2,432 0.51 (0.35-0.73) 81 3,264 0.69 (0.50-0.94) 
 p-interaction=0.15 
IL-2 concentration (pg/ml)
3     
  
    
Quartile 1 124 3,612 Ref 101 3,053 Ref 
Quartile 2 39 1,868 0.64 (0.42-0.96) 33 1,243 1.04 (0.72-1.50) 
Quartile 3 69 2,703 0.69 (0.52-0.93) 79 2,442 1.08 (0.81-1.43) 
Quartile 4 65 2,906 0.71 (0.52-0.96) 79 2,223 1.09 (0.80-1.50) 
 p-interaction=0.07 
Infection type         
 
  
Incident 140 2,908 Ref 148 2,480 Ref 
Prevalent 160 8,388 0.51 (0.39-0.66) 146 6,494 0.45 (0.34-0.59) 
Age (years)         
 
  
<45 63 1,995 Ref 107 2,929 Ref 
45-54 124 4,423 0.79 (0.58-1.07) 137 4,036 0.97 (0.75-1.24) 
≥55 113 4,877 0.67 (0.49-0.92) 50 2,009 0.82 (0.58-1.15) 
HIV and current CD4 cell count (cells/µL)         
 
  






HIV infected, CD4≥500 124 4,386 0.91 (0.67-1.23) 93 3,157 0.80 (0.57-1.12) 
HIV infected, CD4<500 102 4,584 0.86 (0.63-1.18) 148 4,447 0.92 (0.67-1.26) 
 
1
 TNF-α and IL-2 were each analyzed in separate multivariable models adjusting for infection type, age, and HIV status/CD4 count. Covariates shown are from 
the model with TNF-α. Bolding indicates adjusted hazard ratios (aHR) with p<0.05.  
2 
TNF-α quartiles in men: 0.0-2.49 (Q1), 2.50-3.19 (Q2), 3.20-4.39 (Q3), 4.40-14.58 (Q4). TNF-α quartiles in women: 0.0-2.83 (Q1), 2.84-3.94 (Q2), 3.95-5.62 
(Q3), 5.63-19.33 (Q4).  
3 






Chapter 4. The association of recreational drug use with clearance 
or persistence of oral HPV infection 
 
Abstract 
Background: Persistent oral human papillomavirus (HPV) infection increases risk for 
oropharyngeal squamous cell carcinoma (OPSCC). Modifiable risk factors for oral HPV 
persistence are not well understood, but may play an important role in HPV-related 
OPSCC prevention. Recreational drug use can have immunomodulatory effects, but its 
effect on oral HPV infection has not been previously explored. Since recreational drug 
use and HPV-related OPSCC prevalence are higher in HIV-infected individuals, we 
sought to determine whether drug use influences the natural history of oral HPV among 
individuals with or at risk for HIV. 
 
Methods: From 2010 to 2014, Scope
®
 oral rinse and gargle samples were collected from 
1,666 participants semi-annually.  Samples were tested for 37 types of oral HPV DNA 
using PCR with PGMY primers followed by reverse line blot hybridization.  At each 
visit, data were collected on recent (past 6 months) drug use (alcohol, cigarette, 
marijuana, crack, cocaine, heroin, amphetamines, ecstasy/club drugs and speedball; in 
men only, poppers and sexual performance-enhancing drugs). The relationship between 
drug use and oral HPV clearance was evaluated with Wei-Lin-Weissfeld regression 
models, accounting for within-participant clustering of HPV infections. The final 
multivariable model adjusted for biologic sex, HPV infection type (prevalent vs. 
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incident), age (<45, 45-54, ≥55), HIV status, CD4 T cell count (≥500, <500 cells/µL), 
and oral health (saliva amount: normal/too little/too much). 
 
Results: A total of 1,358 type specific oral HPV infections in 594 participants were 
detected and followed for 18,465 person-months. At time of first oral HPV detection, 
participants with HPV DNA detected reported recent use of alcohol (65%), cigarettes 
(47%), marijuana (27%), crack (10%), cocaine (6%), heroin (2%), amphetamines (2%), 
ecstasy/club drugs (0.005%) and speedball (0.002%). HPV-infected men reported use of 
poppers (22%) and sexual performance-enhancing drugs (10%). Median time to 
clearance was 6.3 months (IQR=5.9-12.1). Overall, recent drug use (of any type) was not 
associated with oral HPV clearance. Recent cocaine use was associated with reduced oral 
HPV clearance (HR=0.60, 95% CI=0.41-0.89). In multivariable analysis, recent cocaine 
use remained strongly associated with reduced oral HPV clearance (aHR=0.60, 95% CI 
0.41-0.88). Results were similar when restricted to only HIV-infected participants within 
any one of the CD4 T cell strata (≥500, <500 cells/µl).  
 
Conclusions: This study suggests that cocaine use may reduce clearance of oral HPV 
infection. Other types of recreational drug use did not influence oral HPV clearance.  
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Background and rationale 
Persistent oral human papillomavirus (HPV) infection increases risk for 
oropharyngeal squamous cell carcinoma (OPSCC), but risk factors for oral HPV 
persistence are poorly understood.
19
 Tobacco, alcohol and recreational drugs such as 
marijuana, cocaine, amphetamines and opiates have immunomodulatory effects,
83-87
 but 
their effect on oral HPV natural history is under-explored. 
There is some evidence that cigarette smoking may increase risk for persistent 
oral HPV,
14,15,37,88
 as it does for cervical HPV.
89
 A study of the 6-month natural history of 
oral HPV in women found that oral HPV infections detected at baseline were more likely 
to be detected 6 months later among current smokers (adjusted odds ratio [OR]=8.0; 95% 
CI=1.3-53).
14
 Similarly, a case-control study found that women cigarette smokers had a 
higher risk of persistent oral HPV, as compared to non-smokers (
2
 test, p=0.02; odds 
difference=2.29, 95% CI=1.18-4.44).
88
 A 7-year cohort study in men found that smoking 
increased the risk that oral HPV infection would persist for at least 6 months (adjusted 
OR 1.92; 95% CI=1.05-3.50).
37
 However, there have been contradicting reports that 
smoking has no effect on oral HPV natural history in men.
90,91
 Additionally, questions 
remain about whether HPV clearance and persistence can be affected by the intensity and 
frequency of tobacco use, or simultaneous use of other substances. Interestingly, in a 
study of oral HPV natural history in a drug rehabilitation community where members 
were required to quit cigarette and recreational drug use, complete 1-year clearance of 
oral HPV infection among study participants was suggested to be due in part to smoking 





The effect of active recreational drug use on oral HPV natural history has not 
been previously studied, and data on the effects of alcohol are scant.
15
 Laboratory and 
animal studies have found that alcohol, marijuana, crack, cocaine, amphetamines, opiates 
and a variety of inhalants have immunomodulatory effects, usually depressing but 
sometimes enhancing immune response.
83-85
 These drugs can also decrease host response 
to microorganisms and enhance susceptibility to infection.
83-85
 Tobacco, alcohol and 
recreational drug use are common in individuals with or at risk for HIV,
92-100
 and have 
been linked to altered immune status, despite ART or HAART use.
92-95,101,102
 There is 
growing evidence that certain drugs including cocaine, opiates, marijuana, alcohol and 
methamphetamine increase HIV infection and replication in vitro and in animal models, 
suggesting the possibility of additive or synergistic effects of drug use and HIV on 
immune function.
85,103-106
 Initial studies suggest HIV may be associated with reduced 
clearance, possibly due to HIV-related immunosuppression, but further research is 
needed as results have been mixed.
42,107,108
 
Recreational drugs may also impact oral HPV infection directly. Alcohol and 
cigarettes both contain carcinogens and mutagens,
109-111
 and other drugs such as crack 
cocaine have been shown to cause nuclear alterations in oral mucosal cells.
112-114
 Since 
the oral mucosa is the first site of exposure for many recreational drugs, it is plausible 
that these irritants and toxins may limit oral HPV clearance, but this hypothesis has not 
yet been investigated. The goal of this study was to explore the association of recreational 
drug use with oral HPV clearance in a U.S.-based cohort study of HIV-infected and HIV-
uninfected adults.  
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Methods 
Study design and study population 
From 2010 to 2014, 1,666 participants were enrolled in the “Persistence of Oral 
Papillomavirus Study” (POPS), a longitudinal study for studying oral HPV natural 
history. POPS was nested within two ongoing observational studies of men and women 
with or at risk for HIV: the Multicenter AIDS Cohort Study (MACS) and the Women’s 
Interagency HIV Study (WIHS). POPS participants were enrolled at 6 study centers: 
Baltimore (MACS), Los Angeles (MACS), Pittsburgh (MACS), Brooklyn (WIHS), 
Bronx (WIHS), and Chicago (MACS and WIHS).
65-67
 Each study center’s Institutional 
Review Board approved the study. All participants provided written informed consent.  
 
Data collection 
At each semi-annual study visit, a 30-second Scope
®
 oral rinse and gargle sample 
was collected to obtain oral exfoliated cells for HPV testing. A blood sample was also 
obtained, from which HIV status and CD4 T cell count were determined. 
Participants completed a structured questionnaire about recreational drug use in the 
past 6 months.
115,116








 Amphetamines (e.g. speed, methamphetamines) 
 Ecstasy/club drugs (e.g. ketamine, GHB) 
 Speedball (cocaine and heroin or morphine injected together) 
 “Poppers” or inhaled nitrites (assessed in men only) 
 Sexual performance enhancing drugs (e.g. not prescribed for erectile dysfunction; 
assessed in men only) 
 
At POPS enrollment, participants completed a supplemental questionnaire, which 
assessed oral health (i.e. amount of saliva). Questionnaires were administered via 
Computer-assisted Self-interviewing (CASI) in the MACS and were interview-
administered in the WIHS. (See Appendices B and C for data collection tools) 
 
Oral HPV detection and genotyping 
Oral rinse samples were tested for 37 types of HPV DNA using PCR, followed by 
reverse line-blot hybridization, as described in detail in Chapter 3 Methods section.
68
 
Each sample was evaluated for the presence of high-risk/oncogenic types (16, 18, 31, 33, 
35, 39, 45, 51, 52, 56, 58, 59, 66) and low-risk/non-oncogenic types (6, 11, 26, 38, 40, 
42, 53, 54, 55, 61, 62, 64, 67, 68, 69, 70, 71, 72, 73, 81, 83, 84, 89, IS39), classified 
according to criteria from the International Agency for Research on Cancer.
7,69,70
 
Participants with any of these HPV types were considered HPV-infected. Prevalent oral 
HPV infection was defined as any type-specific oral HPV infection detected at study 
enrollment. Incident infection was defined as newly detected type-specific infection that 
was preceded by at least one HPV-negative oral rinse. 
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Time of oral HPV infection was defined as the visit of first type-specific oral 
HPV detection and clearance was defined as the visit of subsequent HPV-negative oral 
rinse. A secondary stricter definition of oral HPV clearance was also considered, 
requiring 2 consecutive HPV-negative oral rinses. 
 
Statistical methods 
Patient characteristics were summarized using descriptive statistics. Drug use 
prevalence was defined as the number of participants reporting use of each drug at the 
time of oral HPV detection out of 594 HPV-infected participants. Kaplan-Meier survival 
curves were used to plot the influence of drug use on time to clearance. Differences in 
survival curves were assessed using the log-rank test. 
The relationship between use of each drug and type-specific oral HPV clearance 
was evaluated with unadjusted and adjusted WLW regression models,
72
 accounting for 
within-participant clustering of HPV infections. There were few users of speedball and 
ecstasy/club drugs, so these 2 drug types were excluded from analyses of the effect of 
individual drugs on time to clearance but included in calculation of composite drug use 
variables (i.e. use of any drug, poly drug use). 
Variables associated with time to clearance at p<0.10 in univariable (unadjusted) 
analysis were considered for inclusion in the multivariable (adjusted) model and were 
retained in the final model if statistically significant at p<0.05. Some variables (i.e. age) 
were included in multivariable analyses a priori based on prior evidence of being an 
important determinant for clearance of oral HPV infection. A number of potential 
confounders were considered, including HPV type and oral health. AIC, a standard 
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statistical test, was used to test the suitability of the models. The final multivariable 
model adjusted for biologic sex, HPV infection type (prevalent vs. incident), age (<45, 
45-54, ≥55), HIV status, CD4 T cell count (≥500, <500 cells/µL), and oral health (saliva 
amount: normal/too little/too much).  
In the primary analyses, recreational drug use exposure was defined as 
participant-reported use in the past 6 months (i.e. roughly, since the last study visit) and 
was modeled as a time-updated variable (i.e. time-dependent, allowing change of drug 
use status with each subsequent visit). Secondary analyses explored recency of drug use 
(i.e. drug use in the 6 months vs. past 12 months, to account for potential time lag in the 
effects of drug exposure, and because drug effects may persist even after drug cessation 
or with no recent use), drug use reported at time of oral HPV detection only (i.e. drug use 
as a time fixed variable, since drug exposure closer to the time of oral HPV infection may 
be more relevant to oral HPV natural history), and cumulative drug use reported over the 
course of oral HPV infection (to account for additive effects of drugs).  
To test the dose-response relationship of drug exposure to HPV clearance, the 
frequency of drug use was stratified for analyses, with non-users in the lowest category 
and daily users in the highest category. For cigarettes and alcohol use, the intensity of use 
(i.e. packs smoked, number of drinks consumed per day) was assessed. Since poly drug 
use is common in the study population, the total number of drugs used (both including 
and excluding cigarette and alcohol use) was explored. Given the possibility that direct 
trauma to the oral mucosa may impact oral HPV clearance, the effect of any drugs 
smoked/snorted was also examined.  
 44 
Hazard ratios (and 95% CIs) for HPV clearance were compared between 
infections in different drug use categories. Analyses were conducted with Stata12.
73
 




Out of 1,666 participants, 594 HPV-infected participants with 1,358 type-specific 
oral HPV infections were identified. Half of participants (54%) were men, most were of 
Black race (55%), and the median age was 50 years (Table 4-1). Of the participants who 
were HIV-infected (72%), 81% were on current antiretroviral therapy (ART) and half 
(50%) had normal CD4 T cell count (≥500 cells cells/µL).  
At time of first oral HPV detection, HPV-infected participants reported recent use 
of alcohol (65%), cigarettes (47%), marijuana (27%), crack (10%), cocaine (6%), heroin 
(2%), amphetamines (2%), ecstasy/club drugs (0.005%) and speedball (0.002%) (Figure 
4-1). Most participants (86%) reported use of at least 1 drug type (excluding poppers and 
sexual performance-enhancing drugs). Of these participants, 47% reported concurrent use 
of more than 1 drug type. HPV-infected men reported use of poppers (22%) and sexual 
performance-enhancing drugs (10%) (Figure 4-1).  
 
Predictors of oral HPV clearance 
Predictors of oral HPV clearance were evaluated over 18,465 person-months of 
follow-up. Median time to clearance of oral HPV infection was 6.3 months (IQR: 5.9-
12.1) 
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Overall, recent drug use (i.e. use of any drug type) was not significantly 
associated with clearance (HR=0.98, 95% CI=0.83-1.16) (Table 4-2). Recent cocaine use 
was associated with reduced oral HPV clearance (HR=0.60, 95% CI=0.41-0.89) (Table 4-
2, Figure 4-2). While there was some suggestion cocaine use had a stronger effect in 
HIV-infected participants (HR=0.55, 95% CI=0.34-0.87) as compared to HIV-uninfected 
participants (HR=0.86, 95% CI=0.43-1.70), this difference was not statistically 
significant (p-interaction=0.30). The effect of cocaine on clearance was similar for 
oncogenic and non-oncogenic HPV types, and for both men and women. When 
considering any cocaine use in the past year, the association with reduced clearance was 
in the same direction but attenuated (HR=0.82, 95% CI=0.62-1.08). 
Recent (past 6 months) cocaine use remained strongly associated with reduced 
oral HPV clearance (aHR=0.60, 95% CI=0.41-0.88), after adjusting for biologic sex, 
HPV infection type (prevalent vs. incident), age, HIV status, CD4 T cell count, and oral 
health (saliva amount: normal/too little/too much) (Table 4-3). Results were similar when 
restricted to only HIV-infected participants within any one of the CD4 T cell strata 
(≥500, <500 cells/µl). In this adjusted model, male sex (aHR=0.79, 95% CI=0.69-0.91), 
prevalent infection type (aHR=0.43, 95% CI=0.37-0.49) and dry mouth (aHR=0.80, 95% 
CI= 0.65-0.98) remained associated with reduced oral HPV clearance.  
No other drug types were associated with oral HPV clearance, when considering 
use in the past 6 months only, or any use in the past year. For each of the drug types 
analyzed, baseline drug use (reported at the time of oral HPV detection) was not a 
superior predictor of time to clearance, as compared to time-updated drug use. 
Cumulative drug use was not associated with oral HPV clearance. For cigarettes and 
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alcohol use, the intensity of use (i.e. packs smoked, number of drinks consumed per day) 
was assessed but found to not influence oral HPV clearance. When examining cigarette 
smoking categorized by smoking history, current smoking (HR=0.69, 95% CI=0.55-0.87) 
and past smoking (HR=0.75, 95% CI=0.57-0.97) appeared to be associated with reduced 
oral HPV clearance, as compared to never smoking, in women but not men (p-
interaction=0.18). In an adjusted model, smoking was not associated with oral HPV 
clearance for either sex. 
The frequency of use of marijuana, crack, poppers and sexual performance 
enhancing drugs was not significantly associated with time to clearance. There were too 
few cases of oral HPV clearance in cocaine, heroin and amphetamine users to examine 
risk of clearance by frequency of use.  
Poly drug use (i.e. simultaneous use of more than one drug) was not associated 
with oral HPV clearance. When excluding alcohol and tobacco use, use of 2 or more 
drugs was significantly associated with reduced clearance (aHR=0.71, 95% CI=0.54-
0.94), primarily due to the effect of cocaine use. When evaluating drugs by mode of use 
(e.g. any smoked/snorted/inhaled drugs), no associations with oral HPV clearance were 
observed. Comparing mode of use (i.e. snorted vs. injected) among cocaine users only 
was not possible because nearly all cocaine users snorted the drug.   
 
Discussion 
 To our knowledge, this is the first study to explore the association of recreational 
drug use with oral HPV clearance. While most drugs had no effect on oral HPV 
clearance, cocaine use appeared to reduce clearance. 
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Cocaine is a commonly used stimulant drug that blocks the reuptake of 
monoamine neurotransmitters (norepinephrine, serotonin and dopamine) in the brain.
117
 It 
is taken recreationally for its intense euphoric effects. There are approximately 14 million 
to 21 million estimated past-year cocaine users globally and approximately 1.9 million 
past-month cocaine users in the U.S.
118,119
 When snorted, cocaine is rapidly absorbed by 
mucous membranes and reaches systemic circulation within minutes.
120
 Smaller cocaine 
particles can become trapped by tracheobronchial mucous and carried by epithelial cilia 
to the oropharynx, and then become detectable in saliva.
121
  
Animal and human studies have shown that cocaine exposure can have broad 
immunosuppressive effects on leukocyte populations, including T cells, B cells and 
natural killer (NK) cells,
83,84,117,122
 and may differentially stimulate certain T cell 
subsets.
102
 In addition, cocaine can cause imbalances in cytokine production, reducing 
immune responsiveness to viral infections.
83-85,117
 Given that a healthy immune response 
is required for HPV clearance,
46
 the immunosuppressive effects of cocaine may explain 
why those reporting recent use experienced reduced clearance of infection. Direct 
damage to oral mucosal cells may also account for the delayed clearance.
123,124
 
Cocaine use in the 6 months before oral HPV detection was more strongly 
associated with reduced oral HPV clearance than cocaine use in the 12-month period 
before HPV detection. We carefully considered the appropriate time frame for capturing 
the effects of cocaine use, especially since past research has suggested that cocaine 
cessation, in addition to both acute and chronic cocaine exposure, may result in 
immunosuppressive effects.
125
 We found that cocaine use closer to the time of oral HPV 
detection had the greater impact on oral HPV natural history.  
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Given that the degree of immune suppression induced by cocaine exposure 
depends highly on dose and frequency of administration,
117
 it may have been informative 
to evaluate whether frequency of cocaine use affected clearance, but we were limited by 
small sample size. Cocaine is sometimes used in “binges”, especially as it has a relatively 
short-lasting effect and induces physical addiction. Therefore, additional study could 
provide helpful data on whether the intensity of cocaine usage corresponds to reduced 
oral HPV clearance in a dose-response fashion. 
Previous studies have demonstrated that cocaine use increases HIV pathogenesis 
and has detrimental health effects in HIV-infected individuals, even amongst those who 
are ART-adherent.
85,103,126-128
 We considered the possibility that the effect of cocaine use 
on reduced clearance was mediated by HIV-related immune factors. However, we found 
that the effects of cocaine were similar across CD4 T cell strata among HIV-infected 
individuals, suggesting that the effects of cocaine were independent of HIV-related 
immunosuppression. HAART use was also found to be unrelated to oral HPV clearance 
in this study population.  
Poly drug use was common in this study population, as in other high-risk 
populations,
83
 and so it was not possible to isolate the effects of cocaine alone on oral 
HPV natural history. Evidence of cocaine-mediated immunosuppression has been 
repeatedly demonstrated by laboratory studies of cocaine, isolated from the 
contaminating effects of other potentially immunomodulatory drugs.
84
 This supports our 
hypothesis that cocaine-related immunosuppression may lead to reduced oral HPV 
clearance. Also, none of the other drugs studied had any significant impact on oral HPV 
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clearance so it is unlikely that the effects of cocaine observed are due to the effects of 
other drugs used concurrently. 
In this study, crack use was not associated with oral HPV clearance. The reasons 
why cocaine, but not crack, was associated with oral HPV clearance are not clear. As 
crack is derived from powder cocaine (by mixing with a solvent and baking soda), the 
chemical composition of crack and cocaine are very similar and thus their differences are 
primarily in the route of administration.
129
 In this study, cocaine was primarily snorted 
and crack was smoked. It is possible that this difference in drug delivery may have 
accounted for differences in effects, perhaps since snorted cocaine particles are more 
likely to cause micro-abrasions to oral mucosa. Differences in observed effects may also 
be due to solvents used in forming crack cocaine from powder cocaine, or 
contaminants/adulterants added to enhance drug effects or attenuate its side effects
129,130
 
Another potential explanation is that the heat used to smoke crack destroys the active 
drug, or leads to loss by vaporization; indeed, smoking is known to be a less efficient 




This study found that, overall, smoking had no effect on oral HPV clearance. 
These results contrast with other studies that have found smoking to be a risk factor for 
oral HPV persistence.
14,37,88
 This discrepancy may be due to differences in study 
population or in method of oral HPV detection and/or testing. While we used oral rinse to 
obtain exfoliated oral cells, 2 of the prior studies used Cytobrush
®
 oral scrapings from the 
buccal mucosa for oral HPV testing.
37,88
 Both of those studies also used a different testing 
platform and tested for 24 HPV types while we tested for an additional 13 HPV types. In 
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this study, the data suggested that smoking might reduce clearance in women but not 
men. This is consistent with a previous study in this same cohort at 3 years of follow-up, 
which found that HIV-infected women smokers had reduced oral HPV clearance;
15
 
however, differences by HIV status and sex did not reach statistical significance in this 
study. 
It is unclear why alcohol, cigarettes and other drugs with documented immune 
effects (e.g. heroin, amphetamines, marijuana),
83,84
 did not influence oral HPV clearance. 
Self-reported drug use may not reflect biological exposure, and thus, future studies may 




A novel finding in this study was the association of dry mouth with reduced oral 
HPV clearance. Dry mouth has been associated with use of recreational drugs including 
cocaine and other stimulants, various prescription medications and polypharmacy, older 
age, menopause, and a number of medical conditions.
133-136
 Saliva has various 
antimicrobial components including defensins which are antiviral agents,
137
 so it is 
plausible that a reduction in saliva may decrease oral immune defenses, increasing host 
susceptibility to oral HPV persistence. There is prior evidence that other measures of 
poor oral health, including tooth loss or infrequent tooth brushing, are associated with 
oral HPV infection and OPSCC.
3,5,138
 A case-control study found that women with 
persistent oral HPV infection have different salivary composition, including higher 
salivary IgG and lysozyme, than women without oral HPV.
88
 Taken together, this 
evidence supports the hypothesis that oral health, and possibly dry mouth, may play a 
role in oral HPV infection. However, it remains unclear whether dry mouth, and other 
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measures of oral health, affects the composition of saliva or just the amount of saliva. 
Poor oral health is a common health concern among alcohol/drug-abusers so it is possible 
that reduced clearance results from other unmeasured drug-associated factors.
120,139,140
 
Saliva amount in this study was self-reported and although questionnaire-based 
assessment of dry mouth is a commonly used method for clinical diagnosis of dry mouth 
(i.e. xerostomia), objective measurement of salivary gland function and saliva properties 
may clarify the role of local immunity in oral HPV infection. Also, as interest in oral 
immunity has increased, validated tools such as the Xerostomia Inventory have been 
developed for more reliable subjective assessments of dry mouth.
136
 
Our findings should be interpreted within the limitations of the study. Drug use 
and oral health were self-reported and thus subject to recall and other biases. Cocaine use 
was relatively uncommon so analyses stratified by frequency of cocaine use could not be 
done. Strengths of this study included the longitudinal follow-up, high participant 
retention and large number of common recreational drug types assessed. The use of rinse 
and gargle samples enabled collection of cells from the back of the throat and may have 




This study is the first to report that cocaine use may be an important risk factor for 
oral HPV persistence. These initial findings warrant confirmation from other studies and 
populations. Further examination could increase understanding of the effects of 
frequency and intensity of cocaine use, as well as mechanisms by which cocaine use 
might reduce oral HPV clearance.  
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Women (WIHS) 274 46% 




Incident only 189 32% 
Any Prevalent 405 68% 
Age (year) 
  
<45 162 27% 
45-54 258 43% 
≥55 174 29% 
Race/Ethnicity 
  
White, non-Hispanic 186 31% 
Black, non-Hispanic 328 55% 




Baltimore, Maryland  88 15% 
Bronx, New York 93 16% 
Brooklyn, New York 84 14% 
Chicago, Illinois 202 34% 
Los Angeles, California 24 4% 
Pittsburgh, Pennsylvania 103 17% 
HIV status 
  
Uninfected 168 28% 
Infected 426 72% 
Current CD4 T cell count (cells/uL)  
  
≥500 212 50% 
<500 214 50% 
Current HIV RNA viral load (copies/mL) 
  
<200 286 68% 
200-19,999 78 19% 
≥20,000 57 14% 
Current ART use 
  
No 83 20% 
Yes 343 81% 
Amount of saliva (self-reported) 
  
Don't notice/normal  421 77% 
Too little/dry mouth 82 15% 
Too much 46 8% 
1
 All participant characteristics are from the time of oral HPV detection, with the exception of amount of 
saliva, which was reported at time of POPS enrollment. 
 55 
2
 Prevalent infection was defined as oral HPV detected at POPS enrollment. Incident infection was defined 
as newly detected oral HPV preceded by at least one HPV-negative oral rinse. Some participants had 
prevalent infection, followed by incident infection of another HPV type that was included in the analysis.  
3
 Baltimore, Los Angeles and Pittsburgh study sites enrolled men only (MACS). Bronx and Brooklyn study 
sites enrolled women only (WIHS). Chicago study site enrolled both men and women.  
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Table 4-2. Unadjusted associations of recent drug use, demographic and health factors 
with time to clearance among 594 participants with 1,358 oral HPV infections 
Participant characteristic
1 




Alcohol 1.00 (0.87-1.15) 
Cigarettes 1.00 (0.87-1.16) 
Marijuana  0.98 (0.83-1.15) 
Crack 0.99 (0.79-1.23) 
Cocaine 0.60 (0.41-0.89) 












 0.98 (0.83-1.16) 
Sex 
 
Women (WIHS) Ref 








45-54 0.93 (0.79-1.10) 
≥55 0.79 (0.65-0.95) 
 p-trend=0.01 
HIV status and CD4 cell count (cells/uL) 
 
HIV-uninfected Ref 
HIV-infected, CD4≥500 0.98 (0.82-1.16) 
HIV-infected, CD4<500 0.89 (0.74-1.07) 
 p-trend=0.18 
Amount of saliva (self-reported) 
 
Don't notice Ref 
Too little/dry mouth 0.77 (0.62-0.96) 
Too much 1.04 (0.82-1.34) 
 
1
 All participant characteristics are from the time of oral HPV detection, with the exception of amount of 
saliva, which was reported at time of POPS enrollment 
2 
Drug use was considered a time-updated variable (i.e. drug use status reported at each visit during oral 
HPV infection was applied to the WLW model, and was allowed to change if the participant 




Poppers were defined as nitrite inhalants such as amyl, butyl or isopropyl nitrites.  
4 
Sexual performance-enhancing drugs were defined as drugs other than those prescribed by a medical 
provider for a diagnosed erectile dysfunction. 
5 
Any drug used includes use of alcohol, cigarettes, marijuana, crack, cocaine, heroin, amphetamines, 
speedball, and ecstasy/club drugs (excludes poppers and sexual performance-enhancing drugs, which were 
only assessed in men). 
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Table 4-3. Multivariable risk factors for oral HPV clearance among 594 participants with 
1,358 oral HPV infections 
Participant characteristic
1 




Yes 0.60 (0.41-0.88) 
Sex  
Women (WIHS) Ref 
Men (MACS) 0.79 (0.69-0.91) 
Infection type  
Incident Ref 
Prevalent 0.43 (0.37-0.49) 
Age (year)  
<45 Ref 
45-54 0.96 (0.81-1.14) 
≥55 0.93 (0.77-1.11) 
  p-trend=0.42 
HIV status and CD4 cell count (cells/uL)  
HIV negative Ref 
HIV positive, CD4≥500 1.00 (0.84-1.19) 
HIV positive, CD4<500 0.87 (0.73-1.04) 
  p-trend=0.10 
Amount of saliva (self-reported)  
Don't notice Ref 
Too little/dry mouth 0.80 (0.65-0.98) 
Too much 1.09 (0.84-1.41) 
aHR=adjusted hazard ratio 
 
1
 All participant characteristics are from the time of oral HPV detection, with the exception of amount of 
saliva, which was reported at time of POPS enrollment 
2 
Cocaine use was considered a time-updated variable (i.e. cocaine use status reported at each visit during 
oral HPV infection was applied to the WLW model, and was allowed to change if the participant 
started/stopped cocaine use). If a participant missed a visit, the last reported cocaine use status was used in 













Figure 4-1. Prevalence of drug use at time of first oral HPV detection  
 
 
Sex PEDs = sexual performance enhancing drugs  
Drug use was assessed in 594 HPV-infected participants, with the exception of poppers use and sex PED 
use, which were assessed in HPV-infected men only (n=320).  
Not shown in figure: ecstasy/club drugs (0.005%) and speedball (0.002%).  
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Figure 4-2. Time to oral HPV clearance in 594 participants with 1,358 oral HPV 




Chapter 5. The association of medication use with clearance or 




Background: With increasing lifespan of patients with HIV, the number of HIV-infected 
individuals taking multiple medications for comorbidities is increasing. While there is 
accumulating evidence on the immunomodulatory effects of medications for chronic 
conditions, the impact of these medications on oral HPV natural history has not been 
previously studied. Given that prescription medication use is a common exposure, and 
potential risk factor for oral HPV persistence, we conducted a study to investigate 
whether medication use may impact oral HPV natural history.  
 
Methods: From 2010 to 2014, Scope
®
 oral rinse and gargle samples were collected from 
1,666 participants semi-annually.  Samples were tested for 37 types of oral HPV DNA 
using PCR with PGMY primers followed by reverse line blot hybridization.  At each 
visit, data were collected on recent (past 6 months) use of medications, including: 
antiasthmatics, antidepressants, antihypertensives, antipsychotics, anxiolytics and 
sedatives, cholesterol-lowering medications, diabetes medications, hormones, non-
steroidal anti-inflammatory drugs (NSAIDs) and erectile dysfunction medications. The 
relationship between medication use and oral HPV clearance was evaluated with Wei-
Lin-Weissfeld regression models, accounting for within-participant clustering of HPV 
infections. The final multivariable model adjusted for biologic sex, HPV infection type 
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(prevalent vs. incident), age (<45, 45-54, ≥55), HIV status and CD4 T cell count (≥500, 
<500 cells/µL).  
 
Results: A total of 1,358 type specific oral HPV infections in 594 participants were 
detected and followed for 18,465 person-months. In unadjusted analyses, oral HPV 
clearance was significantly reduced in those with recent use of antipsychotics (HR=0.75, 
95% CI=0.57-0.99), anxiolytics/sedatives (HR=0.78, 95% CI=0.63-0.96) and 
antidepressants (HR=0.82, 95% CI=0.67-0.999). Among users of antipsychotics, there 
appeared to be effect modification by HIV status, with reduced clearance in HIV-infected 
participants (HR=0.75, 95%: CI 0.57-0.99), but not HIV-uninfected participants (p-
interaction=0.009). Use of erectile dysfunction medications was marginally associated 
with reduced oral HPV clearance (HR=0.77, 95% CI=0.58-1.01). No other medication 
type was significantly associated with oral HPV clearance. After adjusting for the effects 
of sex, infection type (incident vs. prevalent), age, HIV status and CD4 T cell count, 
antipsychotic use remained significantly associated with reduced oral HPV clearance 
overall (aHR=0.75, 95% CI=0.57-0.99), and when restricted to only HIV-infected 
participants (aHR=0.66, 95% CI=0.48-0.90). Anxiolytics/sedatives, antidepressants and 
erectile dysfunction medications remained associated with reduced clearance but these 
associations were not statistically significant. 
 
Conclusions: Participants using antipsychotic medications had significantly reduced oral 
HPV clearance, with potential differential effects by HIV status. Antidepressants and 
anxiolytics/sedatives were also associated with reduced oral HPV clearance, especially 
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when taken in combination. Each of these medications are prescribed for conditions that 
have immunomodulating effects, so characteristics of the illness may partially contribute 
to reduced oral HPV clearance.   
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Background and rationale 
Antiretroviral therapies (ART) have significantly increased survival of HIV-
infected individuals, transforming HIV into a chronic and manageable condition.
141
 As 
people with HIV live longer, there has been an increase in comorbidities and use of 
medications to treat these conditions.
142,143
 While there is growing evidence on the 
immunomodulatory effects of medications for chronic conditions, the impact of these 
medications on oral HPV natural history is unknown.  Given that prescription medication 
use is a common exposure in individuals with or at risk for HIV,
144
 a population with 
high oral HPV prevalence, we conducted a study to investigate whether medication use 
influences oral HPV clearance.  
 Individuals with HIV suffer from a higher number of comorbidities from a 
younger age and are at greater risk of age-related comorbidities, as compared to HIV-
uninfected individuals.
141,143,145,146
 Studies suggest that HIV infection is associated with 
poorer health, through effects on inflammation and interaction with other risk factors 
common in high-risk populations such as prolonged substance use.
141,144
 In one 
observational study of HIV-infected individuals ≥50 years of age in the UK, 84% of 
participants reported having ≥1 comorbid conditions and 61% reported >2 comorbid 
conditions.
147
 The most commonly reported conditions were high cholesterol, sexual 
dysfunction, hypertension and depression. Indeed, as AIDS-defining illnesses are 
becoming more rare in individuals with ART-suppressed HIV, HIV-associated non-AIDS 
conditions are increasingly common.
141,148
 These include conditions associated with 
advancing age and chronic inflammation including but not limited to diabetes mellitus, 




For each comorbidity diagnosed, more than one type of medication may be 
prescribed for treatment or management of the condition.
145
 As a result, HIV-infected 
individuals are commonly taking multiple medications, in addition to ART, 2 to 3 
decades before HIV-uninfected individuals.
145
 In a cross-sectional study of HIV-infected 
patients in the Southern U.S., 93% were receiving non-ART medications including 
antihypertensives (43%), lipid-lowering agents (34%) and 
antidepressants/antipsychotics/anxiolytics (34%), and the median number of medications 
per patient was 8 (IQR: 6-11).
149
 Concurrent use of multiple medication types is more 
common among older HIV-infected patients, as compared to the elderly in the general 
population.
146
 In a study of 130 HIV-infected patients >50 years of age, more than half 
took five or more different medications, in addition to ART, over a 12-month study 
period.
146
 As HIV-infected individuals age, the number of comorbidities and medications 
prescribed to treat these comorbidities is increasing.
142
  
Several commonly prescribed medication types have been shown to have 

















 erectile dysfunction drugs,
187
 and diabetes medications.
175,188-
193
 While it is plausible that medication use may impact oral HPV natural history, this has 
not been previously investigated. As the MACS and WIHS are aging cohorts with a high 
prevalence of oral HPV, multimorbidity and polypharmacy, this presents an opportunity 





Study design and study population 
From 2010 to 2014, 1,666 participants were enrolled in the “Persistence of Oral 
Papillomavirus Study” (POPS), a longitudinal study for studying oral HPV natural 
history. POPS was nested within two ongoing observational studies of men and women 
with or at risk for HIV: the Multicenter AIDS Cohort Study (MACS) and the Women’s 
Interagency HIV Study (WIHS). POPS participants were enrolled at 6 study centers: 
Baltimore (MACS), Los Angeles (MACS), Pittsburgh (MACS), Brooklyn (WIHS), 
Bronx (WIHS), and Chicago (MACS and WIHS).
65-67
 Each study center’s Institutional 
Review Board approved the study. All participants provided written informed consent.  
 
Data collection 
At each semi-annual study visit, a 30-second Scope
®
 oral rinse and gargle sample 
was collected to obtain oral exfoliated cells for HPV testing. A blood sample was also 
obtained, from which HIV status and CD4 T cell count were determined. 
Participants completed a structured questionnaire about their medication use in the 
past 6 months.
115,116
  Data were collected on recent use of: 
 Antiasthmatics (steroidal and non-steroidal) 
o Asthma medications were classified as steroidal anti-asthmatics, which 
suppress airway inflammation; and non-steroidal anti-asthmatics, or 
bronchodilators, which relax airway smooth muscle. These medications 
are also used to treat chronic obstructive pulmonary disease (COPD). 
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 Antidepressants  
 Antihypertensives  
 Antipsychotics – used to treat schizophrenia, bipolar disorder and related 
psychotic disorders 
 Anxiolytics/sedatives – used to treat a variety of disorders including, but not 
limited to: anxiety, sleeping disorders, epilepsy, alcohol withdrawal and muscle 
spasms. For the purposes of this study, anxiolytics and sedatives are considered a 
single medication group. 
 Cholesterol-lowering medications 
 Diabetes medications 
 Hormones, including hormone replacement therapy (e.g. estrogen, progesterone) 
or hormones used to treat thyroid disorders. This excludes hormones taken only to 
prevent pregnancy but that may be used for hormone replacement therapy 





 Non-steroidal anti-inflammatory drugs (NSAIDs) 
 Erectile dysfunction medications (men only) – used to treat physician-diagnosed 
erectile dysfunction 
At POPS enrollment, participants completed a supplemental questionnaire, which 
assessed oral health (i.e. amount of saliva). Questionnaires were administered via 
Computer-assisted Self-interviewing (CASI) in the MACS and were interview-
administered in the WIHS. (See Appendices D and E for data collection tools) See 
Appendix F for details of medication classifications and examples of medication types 
included in each medication class.  
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Oral HPV detection and genotyping 
Oral rinse samples were tested for 37 types of HPV DNA using PCR, followed by 
reverse line-blot hybridization, as described in detail in Chapter 3 Methods section.
68
 
Each sample was evaluated for the presence of high-risk/oncogenic types (16, 18, 31, 33, 
35, 39, 45, 51, 52, 56, 58, 59, 66) and low-risk/non-oncogenic types (6, 11, 26, 38, 40, 
42, 53, 54, 55, 61, 62, 64, 67, 68, 69, 70, 71, 72, 73, 81, 83, 84, 89, IS39), classified 
according to criteria from the International Agency for Research on Cancer.
7,69,70
 
Participants with any of these HPV types were considered HPV-infected. Prevalent oral 
HPV infection was defined as any type-specific oral HPV infection detected at study 
enrollment. Incident infection was defined as newly detected type-specific infection that 
was preceded by at least one HPV-negative oral rinse.   
Clearance was defined as two consecutive HPV-negative oral rinses, with time of 
clearance as the visit of the first negative oral rinse sample. A secondary less 
conservative definition of clearance was considered, requiring only one HPV-negative 
oral rinse sample. 
 
Statistical analyses  
Participant characteristics were summarized using descriptive statistics. 
Medication use prevalence was defined as the number of participants reporting use of 
each medication at time of oral HPV detection, out of 594 HPV-infected participants. For 
medications that are often prescribed concurrently (e.g. cholesterol-lowering and 
hypertension medications), or that are used to treat illnesses with similar clinical 
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presentations (e.g. antipsychotic and antidepressant medications), the prevalence of 
concomitant medication use was calculated in this same way.  
The analysis included 1,358 type-specific oral HPV infections among 594 
participants (some participants were infected with multiple HPV types at the same visit 
and medication use status reported at that visit was applied to clearance analysis of all 
those infections). The effect of each medication type on oral HPV clearance was modeled 
using WLW models, accounting for within-participant clustering of HPV infections.
72
 
First, the effect of each medication was considered in separate univariable models. Then 
common concomitant medication pairs were also modeled separately to assess whether 
use of both medications together was associated with time to clearance, as compared to 
using only one of these medications or none of these medications. For medications with 
statistically significant associations with time to clearance, the number of these 
medications used concurrently was evaluated to determine whether increasing medication 
use resulted in cumulative effects on clearance.  
Variables associated with time to clearance at p<0.10 in univariable (unadjusted) 
analysis were considered for inclusion in the multivariable (adjusted) model and were 
retained in the final model if statistically significant at p<0.05. Some variables (i.e. age) 
were included in multivariable analyses a priori based on prior evidence of being 
important determinants for clearance of oral HPV infection. A number of potential 
confounders were considered, including HPV type and oral health. AIC, a standard 
statistical test, was used to test the suitability of the models. The final multivariable 
model adjusted for biologic sex, HPV infection type (prevalent vs. incident), age (<45, 
45-54, ≥55), HIV status, and CD4 T cell count (≥500, <500 cells/µL). Stata 12 statistical 
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software package was used for statistical analyses.
73
 Statistical significance was defined 




The study population in this analysis is the same as the one in the analysis of 
recreational drug use (Chapter 4, Table 4-1). Participant characteristics are reproduced 
below for clarity (Table 5-1). Out of 1,666 participants, 594 HPV-infected participants 
with 1,358 type-specific oral HPV infections were identified. Half of participants (54%) 
were men, most were of Black race (55%), and median age was 50 years (Table 5-1). Of 
the participants who were HIV-infected (72%), 81% were on current antiretroviral 
therapy (ART) and half (50%) had normal CD4 T cell count (≥500 cells cells/µL).  
Among 594 HPV-infected study participants, the most commonly used 
prescription drugs were hypertension medications (39% of participants), NSAIDs (39%), 
cholesterol-lowering drugs (27%), antidepressants (25%) and anxiolytics/sedatives (21%) 
(Figure 5-1).  At time of oral HPV detection, 84% of participants reported use of at least 
1 medication (excluding erectile dysfunction medications). Among men only, 17% 
reported use of erectile dysfunction drugs prescribed by a physician. 
At time of oral HPV detection, 34% of participants reported concurrent use of 
more than 1 medication. The most commonly used medication pairs were: cholesterol-
lowering and hypertension medications (15% of all study participants), hypertension and 
diabetes medications (9%), cholesterol-lowering and diabetes medications (7%) and 
antipsychotics and antidepressants (7%) (Figure 5-2). 
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Effect of medication use on time to oral HPV clearance 
Oral HPV clearance was evaluated over 18,465 person-months of follow-up. 
Median time to clearance of oral HPV infection was 6.3 months (IQR: 5.9-12.1) 
In unadjusted analyses, reduced oral HPV clearance was significantly associated 
with recent use of antipsychotics (HR=0.75, 95% CI=0.57-0.99), anxiolytics/sedatives 
(HR=0.78, 95% CI=0.63-0.96) and antidepressants (HR=0.82, 95% CI=0.67-0.999) 
(Table 5-2). Use of erectile dysfunction medications was marginally associated with 
reduced oral HPV clearance (HR=0.77, 95% CI=0.58-1.01). No other medication type 
was significantly associated with oral HPV clearance.  
Among users of antipsychotics, there appeared to be effect modification by HIV 
status, with reduced clearance in HIV-infected participants (HR=0.67, 95% CI=0.49-
0.91), but not HIV-uninfected participants (p-interaction=0.009) (Table 5-2). Although 
statistically significant, the numbers of HIV-uninfected participants reporting use of 
antipsychotics at time of oral HPV detection was small (n=10), which limits 
interpretation of this possible interaction by HIV status. Use of anxiolytics/sedatives and 
antidepressants were more common among HIV-uninfected than HIV-infected 
participants and the associations of these medications did not differ by HIV status (p-
interaction=0.99 and 0.81, respectively). The association of non-steroidal antiasthmatics 
with oral HPV clearance appeared to differ by HIV status (p-interaction=0.012), but the 
association with reduced clearance in HIV-infected participants was non-significant 
(p=0.73).  
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After adjusting for the effects of sex, infection type (prevalent vs. incident), age, 
HIV status and CD4 T cell count, antipsychotic use remained significantly associated 
with reduced oral HPV clearance overall (aHR=0.75, 95% CI=0.57-0.99), and when 
restricted to only HIV-infected participants (aHR=0.66, 95% CI=0.48-0.90) (Table 5-3). 
Anxiolytics/sedatives (aHR=0.89, 95% CI=0.73-1.07), antidepressants (aHR=0.89, 95% 
CI=0.71-1.11) and erectile dysfunction medications (aHR=0.78, 95% CI=0.59-1.05) were 
associated with reduced clearance but these associations were not statistically significant. 
 
Concomitant medication use 
Of the participants using antipsychotics, 67% also reported use of antidepressants 
and 29% also reported use of anxiolytics/sedatives at time of oral HPV detection. When 
evaluating concurrent use of these 3 medications in unadjusted analyses, participants who 
reported recent use of all 3 medications had the greatest reduction in clearance (HR=0.57, 
95% CI=0.35-0.94); followed by participants who used any 2 of these medications 
(HR=0.73, 95% CI=0.55-0.96) or only 1 of these three medications (HR=0.83, 95% 
CI=0.69-1.00), as compared to participants who used none of these medications (p-
trend=0.002) (Figure 5-3). In a fully adjusted model, concomitant use of antipsychotics, 
antidepressants, and anxiolytics/sedatives remained marginally associated with reduced 
clearance, with greater number of medications used being more strongly associated (p-
trend=0.04). When restricting the analyses to use of only antipsychotics, only 
antidepressants or only anxiolytics/sedatives, each medication remained associated with 
reduced clearance, but no longer reached statistical significance. Concomitant use of 
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other medications (i.e. commonly paired medications) was not significantly associated 
with oral HPV clearance. 
 
Discussion 
While most medications did not affect oral HPV clearance, some potentially 
immunomodulatory medications decreased oral HPV clearance.  This effect was most 
notable for anti-psychotic use. In addition to antipsychotics, antidepressants and 
anxiolytics/sedatives appeared to affect oral HPV clearance, especially when these 
medications were taken in combination.  
 
Association of antipsychotic medications and oral HPV clearance 
The immunomodulatory effects of antipsychotics, which are used for treatment of 
schizophrenia or bipolar disorder, have been consistently reported in in vivo, in vitro and 
ex vivo studies.
154-157
 According to a recent meta-analysis, which included 23 studies (762 
subjects being treated for schizophrenia), antipsychotic medications have anti-
inflammatory immune effects, characterized by increased plasma IL-12 and soluble IL-2 
receptor (sIL2R), and decreased IL-1 and IFN-.
157
 However, the nature of cytokine 
alterations (i.e. which cytokines are down-regulated and which are up-regulated) may 
vary depending on patient characteristics. 
154,157
 An independent, more restrictive meta-
analysis of 180 first-episode psychosis subjects across 5 clinical cohorts, found that after 
controlling for age and gender, as well as BMI and smoking when possible, 
antipsychotics had some pro-inflammatory effects, characterized by increased IL-15, in 
addition to anti-inflammatory effects.
154
 Therefore, while there is substantial evidence 
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that antipsychotics induce immunomodulation, it is not clear whether the overall effect is 
anti-inflammatory or pro-inflammatory, limiting our ability to speculate on the 
mechanism by which antipsychotic medications may reduce oral HPV clearance.  
It is also possible that reduced oral HPV clearance is associated with the 
immunomodulatory effects of psychotic disorder, either in addition to or independent of 
any association with the medications used to treat these disorders. Schizophrenia and 
bipolar disorder are commonly diagnosed psychotic conditions. Both of these illnesses 
are characterized by dysregulation of the immune response and upregulation of pro-





efficacy of antipsychotic medications is presumably due to their ability to normalize the 
levels of cytokines that are elevated in patients with psychosis. However, not all 
cytokines are affected by antipsychotics. TNF- concentrations are consistently higher in 
patients with schizophrenia
156,198,199
 and bipolar disorder
200
, as compared to healthy 
controls, and according to a recent meta-analysis, peripheral TNF- concentrations do 
not change upon treatment with antipsychotics.
157
 Furthermore, another meta-analysis 
suggested that TNF-, along with IL-12, IFN- and sIL-2R, may be trait markers for 
schizophrenia as levels remain high even after use of antipsychotics.
156
 If TNF- plays a 
role in oral HPV natural history, as suggested by the results of our study looking at the 
association of serum cytokines with oral HPV clearance (Chapter 3), then this lack of 
effect of antipsychotics on TNF- may help explain why reduced clearance is observed 
in antipsychotics users, even though these medications supposedly normalize cytokine 
levels. This also supports the notion that reduced oral HPV clearance is due to the 
 75 
immunomodulatory effects of psychotic disorder, and not the medications prescribed to 
treat these disorders.  
The association of antipsychotics with reduced clearance could also be explained 
by biological or behavioral factors unique to individuals with psychotic disorders. 
Furthermore, the etiology of psychosis is heterogeneous as it is a symptom of multiple 
mental health illnesses.
201
 For example, atypical antipsychotics are sometimes used for 
treatment of patients with severe or treatment-resistant depressive disorders.
202
 Since 
information on subtypes of psychotic disorders was not available, heterogeneity in study 
participants taking antipsychotics could not be assessed. Variations in antipsychotic 
medication types prescribed (i.e. differences in brand, dose or duration) or differences in 
stage of illness (i.e. first-episode psychosis vs. chronic disease) could also have 
contributed to heterogeneity in this group.  
 
Association of antidepressant use and oral HPV clearance 
In this study, recent use of antidepressants also appeared to be related to reduced 
oral HPV clearance though the effect was not as strong as that observed with use of 
antipsychotics. Evidence from in vivo, in vitro, and ex vivo studies indicate that 
antidepressants have anti-inflammatory effects including suppression of cell-mediated 
immunity and shifting of immune responses from a Th2-like to a Th1-like profile.
150-153
 
Accumulating evidence from clinical studies suggest antidepressants normalize elevated 
systemic cytokine levels,
203-206
 although there are some conflicting results as well as 
limited data on long-term antidepressant use.
153,207
 The immunomodulatory effects of 
antidepressants may explain why they are associated with reduced oral HPV clearance. 
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However, as with psychosis, it is possible that reduced clearance is associated 
with the immunomodulatory effects of depression itself, and not antidepressant use. 
Activation of the inflammatory response in depression has been well-documented, and 
depressive illness (including major depressive disorder and dysthymia, chronic low grade 
depression) is considered an inflammatory disease.
151,152,207-210
 Additionally, infections 
and autoimmune disorders are strong risk factors for major depression so use of 





Association of anxiolytics/sedatives and oral HPV clearance 
Similar to antipsychotics and antidepressants, benzodiazepines, a major class of 
anxiolytic/sedative medications, have immunomodulatory effects. In vitro and murine 
studies have found that benzodiazepines such as alprazolam, diazepam and midazolam 
can disrupt cytokine production as well as suppress macrophage activity and lymphocyte 
proliferation.
158-165
 Studies in mice also indicate that benzodiazepines can increase 







 These effects may be mediated through the interaction of 
benzodiazepines with peripheral GABAA receptors, which play an important role in 
immune responses at mucosal sites.
215
 Most human data are from ex vivo and clinical 
studies of sedative use in patients in critical care settings, and administered by 
injection.
216
 While these studies suggest sedatives have anti-inflammatory effects and 
may increase susceptibility to infection,
216
 it is not conclusive whether these 
immunosuppressive effects are present when used as formulations intended for chronic 
 77 
treatment (i.e. at lower doses and when taken orally). A large case-control study 
(n=34,661) found that use of commonly prescribed benzodiazepines, such as diazepam 
(i.e. Valium) and lorazepam (i.e. Ativan), were significantly associated with increased 
incidence of and mortality from community-acquired pneumonia,
217
 which suggests 
immunosuppressive effects of benzodiazepines in outpatient usage. However, to our 
knowledge, no study has confirmed this via direct measurement of immune biomarkers in 
patients prescribed anxiolytic or sedative treatment for therapeutic indications. Therefore, 
while it is plausible that anxiolytic/sedative-induced immunomodulation may affect oral 
HPV clearance, this explanation is not conclusive. Also, previous research has focused on 
benzodiazepines, which are the most commonly prescribed anxiolytic/sedative. The 
immunomodulatory effects of other anxiolytic/sedative types are unknown.  
The anxiolytics/sedatives user population is difficult to characterize, so while it is 
possible that illness-related characteristics may partially explain reduced clearance 
observed in users, this suggestion should be considered cautiously. Anxiolytics and 
sedatives are most often prescribed for generalized anxiety and stress, but they are used 
broadly for a number of other conditions including epileptic disorders, insomnia or even 
depressive symptoms. Neuropsychiatric disorders such as anxiety and stress can induce 
immunosuppression and alterations in peripheral cytokine profiles,
158,159
 which may 
affect oral HPV clearance independent of anxiolytics/sedatives use. However, illnesses 





Association of other prescription medications and oral HPV clearance 
In this study, erectile dysfunction medications were marginally associated with 
reduced clearance, but reasons for this finding are unclear. Literature on the 
immunomodulatory effects of these medications is sparse. One study showed that 
sildenafil (i.e. Viagra
®
) has immunomodulatory effects in vivo and ex vivo in healthy 
mice, and that these effects are immunosuppressive in male mice but immunostimulatory 
in female mice.
187
 It is not known whether these same effects are present in humans, or if 
other erectile dysfunction medications besides sildenafil have similar side effects. The 
marginal association of erectile dysfunction medications with reduced clearance may be 
influenced by unmeasured sex-related risk factors that delay clearance in men, and that 
perhaps may be linked to the predominance of oral HPV in men, which has been 
consistently reported but not yet been fully explained.
1
 Another potential explanation is 
that reduced clearance may be due to comorbidities associated with erectile 
dysfunction.
218
 Sildenafil is becoming increasingly common as a treatment for pulmonary 
hypertension (Revatio
®
; sildenafil citrate), typically at a lower dose, so it may be helpful 
to explore differences in the effects of sildenafil by treatment indication.
219
  
Other medications with known immunomodulatory effects, such as 
corticosteroids, were not associated with oral HPV clearance. This suggests that perhaps, 
underlying illness, or immune differences between individuals with certain illnesses, may 





Effect of concomitant medication use on oral HPV clearance 
Our analysis of concomitant medication use suggests that neuropsychiatric 
comorbidities, or use of multiple medications to treat these disorders, may reduce oral 
HPV clearance. The effects of antipsychotics, antidepressants and anxiolytics/sedatives 
are difficult to disentangle especially since they are oftentimes prescribed together. 
Concurrent medication use may be due to comorbidity, severe or treatment-resistant 
illness, or multi-symptom clinical presentation.
201,202
 For example, the clinical 
phenotypes for psychosis and depression overlap. Depression is common in patients with 
psychosis, with a prevalence of 25-75%. 
220
 Conversely, patients with depressive 
symptoms may exhibit symptoms of psychosis.
202
 Sleep disturbances and insomnia are 
diagnosed in 30 to 80% of schizophrenic patients, 
220
 so concomitant use of 
anxiolytics/sedatives with antipsychotics is also not uncommon. The nuances of disease 
management may also result in multi-medication use. For example, a patient may 
experience several changes in medication types or dosages, or a trial period of 




In our study population, 67% of the participants who reported using 
antipsychotics were also using antidepressants, which is comparable to the expected 
prevalence of clinical depression in patients with a psychosis disorder diagnosis. 
Simultaneous diagnoses of psychosis and depression appear to result in enhanced 
immunosuppression.
221
 In a study of patients with first-episode psychosis, TNF- and IL-
4 were significantly higher in patients with a concurrent diagnosis of clinical depression, 
as compared to patients with psychosis only.
221
 Therefore, the cumulative effects of 
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comorbidity, may explain why the oral HPV clearance is reduced to a greater degree with 
concurrent users of antipsychotics and antidepressants, as compared to users of only one 
or neither of these medications. While we examined the effects of recreational drug use 
and medication use on oral HPV infection separately, it is important to acknowledge that 
use of recreational drugs may influence medication clearance and activity levels, 




Strengths of this study included the large population size, longitudinal follow-up 
and centralized testing of oral HPV infection. In addition, detailed time updated 
information on medication use was available and collected on validated survey 
instruments administered by experienced research staff that participants knew well. 
This study had several limitations. Medication use was self-reported and we 
cannot exclude the possibility of misclassification bias. Data on dose and frequency of 
medication use were not available. Our analysis does not take into consideration 
differences in drug formulations or medication subtypes. In the future, research on newer 
drug types such as olanzapine for psychosis disorders, which is becoming more widely 
prescribed, may provide additional insight on the impact of these medications on oral 
HPV infection.  
 
Conclusion 
In summary, we found significantly reduced oral HPV clearance in participants 
using antipsychotic medication, with potential differential effects by HIV status. 
Antidepressants and anxiolytics/sedatives may also be associated with reduced clearance, 
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especially when taken in combination. Each of these medications are prescribed for 
conditions that have immunomodulatory effects, so characteristics of the illness may 
partially contribute to reduced oral HPV clearance. The results of this study contribute 
evidence that immune differences may explain why some people clear oral HPV while 
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Women (WIHS) 274 46% 




Incident only 189 32% 
Any Prevalent 405 68% 
Age (year) 
  
<45 162 27% 
45-54 258 43% 
≥55 174 29% 
Race/Ethnicity 
  
White, non-Hispanic 186 31% 
Black, non-Hispanic 328 55% 




Baltimore, Maryland  88 15% 
Bronx, New York 93 16% 
Brooklyn, New York 84 14% 
Chicago, Illinois 202 34% 
Los Angeles, California 24 4% 
Pittsburgh, Pennsylvania 103 17% 
HIV status 
  
Uninfected 168 28% 
Infected 426 72% 
Current CD4 T cell count (cells/uL)  
  
≥500 212 50% 
<500 214 50% 
Current HIV RNA viral load (copies/mL) 
  
<200 286 68% 
200-19,999 78 19% 
≥20,000 57 14% 
Current ART use 
  
No 83 20% 
Yes 343 81% 
Amount of saliva (self-reported) 
  
Don't notice/normal  421 77% 
Too little/dry mouth 82 15% 





 All participant characteristics are from the time of oral HPV detection, with the exception of amount of 
saliva, which was reported at time of POPS enrollment. 
2
 Prevalent infection was defined as oral HPV detected at POPS enrollment. Incident infection was defined 
as newly detected oral HPV preceded by at least one HPV-negative oral rinse. Some participants had 
prevalent infection, followed by incident infection of another HPV type that was included in the analysis.  
3
 Baltimore, Los Angeles and Pittsburgh study sites enrolled men only (MACS). Bronx and Brooklyn study 




Table 5-2. Unadjusted associations of recent medication use with time to oral HPV 
clearance among 594 participants with 1,358 oral HPV infections 








HR (95% CI) 
Antipsychotics




No 122 3,968 Ref 




No 466 14,998 Ref 




No 512 16,123 Ref 




No 466 14,415 Ref 




No 572 19,288 Ref 





No 489 16,349 Ref 




No 469 15,742 Ref 




No 567 19,231 Ref 




No 618 20,665 Ref 




No 397 13,246 Ref 




No 419 11,760 Ref 
Yes 203 6,673 0.90 (0.76-1.07) 
Erectile dysfunction (men only) 
  
  
No 296 9,952 Ref 
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Yes 56 2,419 0.77 (0.58-1.01) 
 
1 
All medication use variables were time-updated (i.e. medication use status reported at each visit during 
oral HPV infection was applied to the WLW model, and was allowed to change if the participant 
started/stopped medication use). If a participant missed a visit, the last reported medication use status 
was used in the analysis. 
Statistically significant values are listed in bold. Statistical significance was defined as two-sided p-value 
<0.05 or 95% confidence interval that does not include 1.0. 
2 
Antipsychotic medication use was associated with reduced clearance in HIV-infected participants only 
(p-interaction=0.009) 
3 
There appeared to be effect modification by HIV status for non-steroidal antiasthmatics (p-





Table 5-3. Multivariable risk factors for oral HPV clearance among 594 participants with 





aHR (95% CI) 
Antipsychotics use
3   
HIV-uninfected   
No Ref 
Yes 1.62 (0.96-2.73) 
HIV-infected   
No Ref 
Yes 0.66 (0.48-0.90) 
Anxiolytics/sedatives use   
No Ref 
Yes 0.89 (0.73-1.07) 
Antidepressant use   
No Ref 
Yes 0.89 (0.71-1.11) 
Sex   
Women (WIHS) Ref 
Men (MACS) 0.87 (0.73-1.04) 
Infection type   
Incident Ref 
Prevalent 0.47 (0.39-0.56) 
Age   
<45 Ref 
45-54 0.91 (0.75-1.11) 
≥55 0.79 (0.56-0.97) 
  p-trend=0.05 
HIV status and CD4 T cell 
count 
  
HIV negative Ref 
HIV positive, CD4≥500 0.91 (0.72-1.15) 
HIV positive, CD4<500 0.84 (0.67-1.04) 
  p-trend=0.11 
1 
Covariates shown are for multivariable model with antipsychotics. Similar covariates for model with 
antidepressants and model with tranquilizers. Each medication modeled separately. 
2 
All medication use variables were time-updated and refer to use of medication since the last study visit. 
HIV status and CD4 count were not time-updated; value from visit of oral HPV detection was used in the 
analysis 
Statistically significant values are listed in bold. Statistical significance was defined as two-sided p-value 
<0.05 or 95% confidence interval that does not include 1.0. 
Adjusted for cohort/sex, type of infection (prevalent/incident), age, HIV status and CD4 count; aHR = 
adjusted hazard ratio 
3 
Antipsychotic medication use was associated with reduced clearance in HIV-infected participants only 
(p-interaction=0.009) 
 88 
Figure 5-1. Prevalence of medication use at time of first oral HPV detection  
 
 
Medication use is shown for men (n=320) and women (n=274) together, with the exception of erectile dysfunction medications, which were assessed in men 
only.  




Figure 5-2. Prevalence of concomitant medication use at time of oral HPV detection  
 
 
Medication use is shown for men (n=320) and women (n=274) together, with the exception of erectile 
dysfunction medications, which were assessed in men only.  
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Figure 5-3. Time to oral HPV clearance among 594 participants with 1,358 oral HPV 




Chapter 6. Epidemiology of HPV-associated cancers in Singapore 
 
This chapter is modified from a paper published in PLOS ONE. “Incidence, trends and 




Background: In recent decades, several Western countries have reported an increase in 
oropharyngeal and anal cancers caused by human papillomavirus (HPV). Trends in HPV-
associated cancers in Asia have not been as well described.  
 
Methods: We describe the epidemiology of potentially HPV-related cancers reported to 
the Singapore Cancer Registry from 1968-2012. Analysis included 998 oropharyngeal 
squamous cell carcinoma (OPSCC), 183 anal squamous cell carcinoma (ASCC) and 
8,019 invasive cervical cancer (ICC) cases. Additionally, 368 anal non-squamous cell 
carcinoma (ANSCC), 2,018 non-oropharyngeal head and neck carcinoma (non-OP 
HNC), and 11,627 nasopharyngeal cancer (NPC) cases were included as comparators. 
Age-standardized incidence rates (ASR) were determined by gender and ethnicity 
(Chinese, Malay and Indian). Joinpoint regression was used to evaluate annual 
percentage change (APC) in incidence.  
 
Results: OPSCC incidence increased in both genders (men 1993-2012, APC=1.9%, 
p<0.001; women 1968-2012, APC=2.0%, p=0.01) and was 5 times higher in men than 
women. In contrast, non-OP HNC incidence declined between 1968-2012 among men 
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(APC= -1.6%, p<0.001) and women (APC= -0.4%, p=0.06). NPC incidence also declined 
in both genders (men 1988-2012, APC= -2.64%, p<0.001; women 1988-2012, APC= -
3.92%, p<0.001). ASCC and ANSCC were rare (ASR=0.2 and 0.7 per 100,000 person-
years, respectively) and did not change significantly over time except for increasing 
ANSCCs in men (APC=2.8%, p<0.001). ICC was the most common HPV-associated 
cancer (ASR=19.9 per 100,000 person-years) but declined significantly between 1968-
2012 (APC= -2.4%). Incidence of each cancer varied across ethnicities.  
 
Conclusions: Similar to trends in Western countries, OPSCC incidence increased in 
recent years, while non-OP HNC decreased. In contrast to OPSCC, NPC incidence also 
decreased in recent years, suggesting a shift in risk factor profile for head and neck 
cancers in Singapore. ICC remains the most common HPV-related cancer in Singapore, 
but Pap screening programs have led to consistently decreasing incidence.  
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Background and rationale 
Human papillomavirus (HPV), a common sexually transmitted infection, causes 
approximately 4.8% of all cancers worldwide, including nearly 100% of cervical cancers, 
most (90%) anal cancers, and 35-80% of oropharyngeal cancers.
6,8,10,223,224
 Epidemiologic 
and molecular data indicate that HPV is an increasingly important risk factor for cancer, 
especially as tobacco-related cancers decline in many countries.
2,10,20,225
  
The epidemiology of HPV-associated cancers varies geographically and between 
racial/ethnic groups, likely due to differences in patterns of tobacco use or in sexual 
behaviors that lead to HPV infection.
10,17,20,223,226-231
 Accumulating evidence from 
countries in North America and Europe (e.g. USA, Canada, Denmark, The Netherlands, 
the UK, Norway) show that the incidence of HPV-associated oropharyngeal squamous 
cell carcinoma (OPSCC) and anal squamous cell carcinoma (ASCC) has increased over 
the past 2 to 4 decades, particularly among men.
2,18,225-234
 Data on the epidemiology of 
HPV-associated cancers in Asia are more limited, but cancer registry-based studies in 
Korea and Taiwan found similar increases in HPV-related OPSCC.
235,236
 Other studies 
suggest that the incidence of OPSCC in some regions (e.g. Hong Kong, Chennai India, 
Singapore) was stable or decreasing from the 1980s to early 2000s.
17,20
 Trends across 
Asian ethnic groups have not been previously studied. Ethnic disparities have been 





 and liver cancers,
237,238
 but are less clear 
for oropharyngeal and anal cancers. 
To contribute Asian data on this topic, we sought to characterize the 
epidemiology of potentially HPV-associated cancers in Singapore, focusing on 
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oropharyngeal, anal and cervical cancers. The epidemiology of nasopharyngeal cancers 
was also evaluated, as it is an infection-associated head and neck cancer endemic to this 
region and is known to affect Asian ethnic subgroups disproportionately.
239
 Singapore is 
a high-income, multicultural city-state of 4 million residents in Southeast Asia with 3 
primary ethnicities – Chinese (74.2%), Malay (13.3%) and Indian (9.2%), which allowed 
description of ethnic variations in cancer incidence.
240
 We evaluated oropharyngeal, anal, 
cervical and nasopharyngeal cancers in Singapore over 4 decades to: 1) determine cancer 
incidence, by type, gender and ethnicity, and 2) characterize temporal trends in these 
cancers.  
Methods 
Case inclusion and classification 
We restricted our analysis to confirmed incident cancers at anatomic sites where 
HPV is known to be a primary cause, including oropharyngeal squamous cell carcinoma 
(OPSCC), anal squamous cell carcinoma (ASCC) and invasive cervical cancer (ICC). We 
included non-oropharyngeal head and neck squamous cell carcinoma (non-OP HNC), 
which is primarily tobacco-related,
1
 and nasopharyngeal cancer (NPC), which is Epstein-
Barr virus (EBV)-related,
241
 as comparators to OPSCC. We included invasive anal non-
squamous cell carcinoma (ANSCC) as a comparator to ASCC.  
Cancer sites were defined according to International Classification of Diseases 
codes for oncology (ICD-O-3). Tumor HPV status was not available, so tumor site was 
used as a proxy to classify cases as “HPV-related” and “HPV-unrelated”, similar to 
previous research.
18,20,225,226,230,232,233,235,236,242
 OPSCC sites included the oropharynx 
(C10.0-C10.4, C10.8-C10.9), tonsil (C02.4, C09.0-C09.1, C09.8-C09.9), base of tongue 
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(C01.9), soft palate and uvula (C05.1-C05.2), and Waldeyer’s ring (C14.2). Non-OP 
HNC sites included other parts of the tongue (C02.0-C02.3, C02.8-C02.9), mouth (C04.0-
C04.1, C04.8-C04.9; C06.0-C06.2, C06.8-C06.9), gum (C03.0-C03.1, C03.9), and hard 
palate (C05.0, C05.8-C05.9). OPSCC and non-OP HNC analyses were restricted to 
cancers with squamous cell histologies (ICD-O-3 codes: 8050 to 8076, 8078, 8083, 8084, 
8094). ICC included endocervix (C53.0), exocervix (C53.1), and cervix uteri (C53.8, 
C53.9). All histologic types of ICC were included as nearly all ICC is due to HPV 
infection.
224
 Invasive anal cancers (C21.0-C21.8) were subdivided into squamous and 
non-squamous histology. Historically, there has not been a widely accepted definition of 
the outer limits of the anal canal.
228
 To reduce likelihood of misclassification error, we 
excluded perianal cancers, which were coded such that they could include skin cancers. It 
is possible that some more distally located HPV-associated anal cancers may be coded as 
skin or perianal cancers, so our classification of potentially HPV-associated anal cancers 
is conservative. NPC included all nasopharynx sites (C11.0-C11.3, C11.8-C11.9). 
 
Data sources 
The numbers of newly diagnosed cancer cases reported between 1968-2012 were 
obtained from the Singapore Cancer Registry, a population-based registry covering all 
Singapore residents. The Ministry of Health Singapore enacted the National Registry of 
Diseases Act in 2007 to ensure comprehensive notifications of cancer cases (local and 
foreign residents) by healthcare institutions in Singapore. The Singapore Cancer Registry 
includes 1.09% death certificate only cases and 91.8% morphologically verified cases 
(unpublished information). Case counts were obtained in aggregate form, by 5-year 
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calendar period (i.e. 1968-72, 1973-77…2008-2012) and age groups (i.e. 20-24, 25-
29…65-69, ≥70). Data were further subdivided by gender and ethnicity. Cancer registry 
information was based on data from medical professionals, pathology records and 
hospital records.
238
 Population denominators for incidence rates were derived from mid-
year population estimates from the Singapore Department of Statistics for each year from 
1968 to 2010 and extrapolated for 2011 and 2012 based on 2010 estimates. Prior to 1980, 
population denominator data collected by the Singapore Department of Statistics included 
individuals on temporary residence permits (e.g. work permits, student passes) while 
cancer case counts included residents only. This inflation of the denominator could have 
resulted in an underestimation of incidence prior to 1980; however, the non-resident 
population was small during this time so underestimation is expected to be minimal.  Our 
analysis used aggregated, de-identified patient data only. Permission was obtained from 
the Singapore National Diseases Registry Office and was approved as exempt from IRB 
review by the National University of Singapore IRB. 
 
Statistical analyses  
Crude incidence rates for each 5-year period were calculated for each cancer type, 
overall and by gender and ethnicity. Age-standardized incidence rates (ASR) per 100,000 
person-years were calculated using the direct method
243
 and based on the WHO world 
standard population.
244
 Incidence rate ratios (IRRs) compared men and women overall 
and for each cancer type. Stata 12 software was used.
73
 
Temporal trends in ASR (5-year periods) for each cancer were characterized 
using the Joinpoint Regression Program, version 4.1.1.
245
 This method uses least squares 
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regression to fit line segments to the natural log of the ASR, joined at discrete points 
(midpoint of 5-year periods) identified by the software to represent statistically 
significant changes in direction of trend.
245
 Models with a minimum of 0 joinpoints (1 
straight line) and maximum of 1 joinpoint (two line segments) were tested sequentially 
using Monte Carlo permutation tests to determine the appropriate number and placement 
of joinpoints, if any.
246
 The simpler, straight-line model was chosen as the final model 
unless the addition of a joinpoint resulted in a significantly better fit. The average annual 
percentage change (APC) in ASR was calculated and considered significant at p≤0.05. 
Temporal trends were explored by gender for all cancer types. Temporal trends in ICC 
and NPC were also explored when stratified by Chinese, Malay and Indian ethnicities. 
The “Other ethnicity” category was excluded from ethnicity-stratified analyses because 
the number of cancers was too few for reliable results, but was included in overall and 
gender-stratified analyses. Due to low numbers, ethnicity-stratified joinpoint results are 
not reported for OPSCC, non-OP HNC and anal cancers. 
 
Results   
Between 1968-2012, 9,200 potentially HPV-associated cancers were diagnosed in 
Singapore including 998 OPSCC, 183 ASCC and 8,019 ICC. There were 2,018 non-OPC 
HNC 368 ANSCC and 11,627 NPC diagnosed during the same period (Table 6-1). The 
incidence of each cancer increased with age, and the median age at diagnosis for OPSCC, 
non-OP HNC, ASCC, ANSCC, ICC and NPC was 62, 61, 66, 66, 53 and 48 years, 
respectively. 
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Gender disparities in age-standardized incidence rates were observed for most 
cancer types. OPSCC, non-OPC HNC, ANSCC and NPC occurred significantly more 
frequently in men than women, while ASCC incidence was similar in men and women 
(Table 6-2).  ICC accounted for 87% of all HPV-associated cancers (ASR=19.9 per 
100,000 person-years). The incidence of OPSCC (ASR=1.4 per 100,000 person-years) 
and ASCC (ASR=0.3 per 100,000 person-years) were lower. 
 
Incidence trends 
Trends in OPSCC and non-OP HNC (Figure 6-1), ASCC and ANSCC (Figure 6-
2), ICC (Figure 6-3) and NPC (Figure 6-4) between 1968-2012 were explored. In the last 
20 years (1993-2012), OPSCC incidence increased steadily in men (APC=1.9%, 
p<0.001) and women (APC=2.0%, p=0.01) (Figure 6-1). In contrast, non-OP HNC 
incidence decreased in men (APC=-1.6, p<0.001) and women (APC=-0.4, p=0.06) during 
this time period. In previous time periods (1968-1992), the incidence of both OPSCC and 
non-OP HNC decreased in men, but only decreased for non-OP HNC in women (Figure 
6-1).  
Analyses of anal carcinomas by histologic subtype suggested different trends over 
time in ASCC and ANSCC. ASCC incidence appeared to decrease from 1968 to 2012 in 
both genders. In contrast, ANSCC incidence appeared to increase during this same period 
(Figure 6-2). The increase in ANSCC incidence in men was significant (APC=2.8%, 
p<0.001), but other observed ASCC and ANSCC trends were not statistically significant. 
ICC incidence declined consistently across all ethnicities, most notably in Indian 
women, who experienced an average -6.78% (p<0.001) decrease in ASR per year 
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between 1978-2012; ICC incidence decreased from 47.2 to 4.7 per 100,000 person-years 
during this time period (Figure 6-3, Table 6-4). ICC incidence also decreased in Chinese 
women, primarily from 1993-2012 (APC= -4.8%, p<0.001). In the most recent time 
period (2008-2012), the overall incidence of ICC in Singapore (ASR=11.6 per 100,000 
person-years) remained lower than the global estimated burden (ASR=15.2 per 100,000 
person-years) but slightly higher than the average rate in more developed countries 
(ASR=9.0 per 100,000 person-years).
247
  
NPC incidence declined consistently for Chinese men and women, with the 
greatest drop in incidence occurring between 1988-2012 (APC, men= -2.64%, p<0.001; 
APC, women= -3.92%, p<0.001) (Figure 6-4). Rates in Malay men increased during this 
same period (APC=1.10, p=0.01) while rates in Malay women, Indian men and Indian 
women remained consistently low and stable from 1968-2012 (Figure 6-4). In the most 
recent time period (2008-2012), the overall NPC incidence in Singapore (ASR=9.7 per 
100,000 person-years) remains higher than NPC incidence in parts of the world where 
this cancer is not endemic (<1 per 100,000 person-years). 
 
Ethnic differences 
 Ethnic differences in the incidence of potentially HPV-associated cancers (OPC, 
ASCC and ICC) were observed. Chinese women had higher risk of HPV-associated 
cancer overall (ASR=22.0 per 100,000 person-years) compared to Malay (ASR=14.7, 
p<0.001) or Indian (ASR=14.9, p<0.001) women, primarily due to higher ICC incidence 
in Chinese women (Table 6-3). In contrast, Indian men had higher risk of HPV-
associated cancer (ASR=4.0 per 100,000 person-years) compared to Chinese (ASR=2.7, 
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p<0.001) or Malay (ASR=1.1, p<0.001) men, primarily due to high OPSCC incidence 
among Indian men (Table 6-3; Table 6-5).  When considering only the most recent time 
period (2008-2012), these same ethnic variations remain.  
 
Discussion  
This study suggests that there are gender and ethnic differences in the incidence 
and temporal trends of potentially HPV-associated cancers in Singapore. Incidence of 
HPV-associated cancer overall was higher in women than men, due to the burden of 
cervical cancer among women, but OPSCC incidence was significantly higher in men 
than women. Ethnic differences in incidence of HPV-associated cancer were observed, 
with higher rates overall among Indian men and among Chinese women than other 
ethnicities. Over the 45 years studied, ICC, non-OP HNC and NPC incidence decreased 
significantly in Singapore, but OPSCC rates increased in both men and women in recent 
years. This research suggests the distribution of HPV-associated cancers across 
population subgroups has changed over the past few decades, possibly mirroring changes 
in tobacco and sexual risk factors.  
Similar to trends reported in other countries of comparable socioeconomic status, 
the incidence of OPSCC in Singapore is rising.
2,10,17,18,20,225,226,230-236
 However, unlike 
some other countries where this increase was only observed in men,
1,2,10 
OPSCC 
incidence in Singapore appeared to increase for both genders.  Recent research suggests 
increases in OPSCC are largely explained by HPV and are likely driven by changing 
sexual practices.
10,20,231,248
 In the current study, tumor HPV status was not available, so 
we do not know what proportion of the OPSCC cases included in our analysis was HPV-
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positive and how this proportion differed by gender and ethnicity, or changed over time. 
Given that the observed patterns in OPSCC incidence differed in men and women, it is 
possible that changing sexual practices may not fully explain trends.  
The recent increasing trend in OPSCC contrasts with consistently decreasing rates 
of non-OP HNC, which are more strongly tied to tobacco usage. Decreasing OPSCC 
incidence in men in the 1970s and 1980s is likely related to declining tobacco use, 
including decreasing popularity of traditional smoking methods such as hand-rolled 
cigarettes (“ang hoon”). Smoking prevalence in Singapore has been declining in men 
since the 1970s and has remained low (<5%) in women,
249,250
 consistent with observed 
decreases in non-OP HNC in this study and decreasing lung cancer rates reported 
elsewhere.
238,250
 The overall incidence of non-OP HNC in Singapore is lower than that in 
North America and Europe,
17,251
 consistent with the lower smoking rate in Singapore 
(~13%).
249
 Tobacco use in Singapore is amongst the lowest in developed countries, 
largely due to the success of anti-tobacco campaigns, legislation on tobacco taxation and 
prohibition of smoking in public places.
249
 Given the low smoking prevalence, the 
epidemiology of non-OPC in Singapore may reflect the HNC profile we will see in other 
settings as tobacco cessation efforts continue.  
Increasing OPSCC also contrasts with decreasing NPC, which is a non-HPV-
related head and neck cancer. Similar decreases in NPC incidence have been observed in 
other urban EBV-endemic regions with large Chinese populations, such as Hong Kong, 
Shanghai and Taiwan,
252-255
 and have been attributed to diet and lifestyle changes, 
particularly since NPC incidence has remained stable in rural areas or parts of Mainland 
China where traditional dietary practices have been maintained.
239,256,257
 Higher NPC risk 
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among ethnic Chinese is well-known, and this is reflected in several-fold lower incidence 
in Malay and Indian ethnicities across all time periods studied.
239
 Increasing NPC 
incidence among Malay men has been previously reported and may reflect changes in 
environmental risk factors, including occupational exposures in the migrant Malay 
population.
258
 Although NPC remains the most common cause of head and neck cancer in 
Singapore, declining trends are encouraging. Furthermore, the divergent OPSCC and 
NPC trends highlight the distinct risk factor profiles of these cancers; increasing OPSCC 
may be an emerging health concern especially if overall NPC incidence continues to 
decline. 
Overall, anal cancer is an uncommon malignancy in Singapore. The observed 
ASCC and ANSCC rates were 2- to 4-fold lower in Singapore than in Western countries 
(typically 1-2 cases per 100,000 in the general population), probably reflecting 
differences in sexual habits in the Singapore population.
228
 Unlike some other countries, 
ANSCC in Singapore is more common among men than women, although numbers for 
both genders are low.
259,260
 The observed increase in incidence of ANSCC is similar to 
the increasing incidence of colorectal cancer during roughly this same time period.
261
 
Colorectal cancer is the most common cancer among males in Singapore, primarily has 
non-squamous cell histology and increases in incidence have been attributed to diet and 
lifestyle changes in older men.
261
 If ANSCC and colorectal cancer have similar risk 
factors, this could explain the sharp increase in ANSCC observed during the study 
period. The strongly divergent trends in ASCC and ANSCC over time suggest etiologic 
differences and the importance of distinguishing anal cancers by histologic type in future 
reports of cancers at HPV-related subsites. 
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Despite substantial decreases in the incidence of ICC in Singapore over the past 4 
decades, ICC remains the most common HPV-associated cancer in Singapore. The 
incidence of ICC in Singapore remains high compared to Western countries of similar 
economic status.
247,262
 However, consistent with previous studies,
238,262
 we observed an 
encouraging decline in ICC rates during the time period of our study. This is largely 
attributed to opportunistic Pap screening which has been available since 1964, and a 
national cervical cancer screening program implemented in 2004, both of which have 
contributed to early detection and treatment of cervical pre-cancers.
262-264
  
The national ICC screening program, which targets sexually active women 
starting at age 25, has successfully expanded coverage with comparable reach for 
Chinese, Malay and Indian ethnicities for first screens.
262,265
 Health surveys conducted in 
2008 and 2010 found that Malay women had a higher rate of loss to re-screen, followed 
by Indian and then Chinese women, which may explain why ICC rates have decreased 
the least in Malay women.
263,265
 However, it is unclear why Chinese women remain at 
higher risk of ICC, as compared to Malay and Indian women in Singapore. In the future, 
increasing Pap screening coverage above the current 50-80%, and ensuring women 





, Merck & Co., Inc., Whitehouse Station, NJ, USA and 
Cervarix
®
, GlaxoSmithKline Biologicals, Rixensart, Belgium) are licensed for use in 
Singapore, but must be covered by out-of-pocket expenses, or Medisave, a compulsory 
health savings scheme where individuals put aside part of their income to pay future 
medical expenses for themselves or dependents.
262,266
 Implementation of a national HPV 
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vaccination program or provision of subsidies for low-income individuals could also 
contribute to future declines in incidence of ICC, and other HPV-associated cancers.  
Although women experience the greater HPV-associated cancer burden in 
Singapore, our results suggest that men may also benefit from prevention efforts targeting 
these cancers as they bear a greater risk of OPSCC. Compared to other cancers in 
Singapore,
238
 OPSCC is relatively rare, and rates in Singapore are lower than in other 
economically developed countries.
2,17
 However, men are disproportionately affected and 
rates are increasing. Although HPV vaccination efforts in Singapore are primarily 
focused on women, and the impact of HPV vaccine on OPSCC has not been fully 
studied, initial research suggests HPV vaccination will likely also be effective in 
preventing oral HPV infection and thus could impact OPSCC rates.
267,268
 Should HPV 
prevention efforts be scaled up in Singapore, our study provides baseline data on the 
incidence of potentially HPV-associated cancers during time periods when HPV 
vaccination coverage is minimal.  
Although the cancers in our analysis are at HPV-related sites, HPV may be just 
one of the factors contributing to observed cancer epidemiology. The heterogeneity in 
patterns of HPV-associated cancer that we observed across ethnic groups could reflect the 
effects of sociocultural practices, genetics, environmental exposures or an interaction 
between etiologic factors. Since the 1960s, Singapore has undergone rapid economic 
development and has become increasingly ‘westernized’ in its transition from a 
developing country to a high-income country and commercial hub in Southeast Asia. 
This has been accompanied by changes in diet, lifestyle and customs that have been cited 
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Differences between ethnic groups in lifestyle factors such as tobacco use and 
sexual norms may contribute to observed differences in HPV-related cancer incidence. 
For instance, Indians are known to have a high prevalence of tobacco and betel quid use, 
practices which increase risk of head and neck cancers.
271-274
 The higher incidence of 
OPSCC observed in Indian Singaporean men and women could be due to early life 
exposure to betel quid in their country of origin or continuation of betel use habits after 
immigration to Singapore. Lower incidence of non-OP HNC among Malays is surprising 
given that their smoking rates are higher than the general Singaporean population (18.6% 
to 30.8% between 1979-2010),
250
 but Malays also have low lung cancer incidence 
suggesting that factors other than smoking exposure may account for differences in 
cancer incidence.
250,273
  Overall, Malays have the lowest HPV-associated cancer 
incidence, compared to Chinese and Indian ethnic groups. This may be due to lower risk 
of HPV infection, or possibly other lifestyle factors that may be protective of cancers. 
Most Malays are Muslim, and they may adhere to a more traditional lifestyle (i.e. diet, 
sexual behaviors) despite Singapore’s modern environment.
258
 It is also possible that 
ethnicity does not fully encompass behavioral, sociocultural and genetic differences and 
that the broad ethnic categorizations used may obscure relevant within-group differences 
in practices or behaviors.   
Limitations of this study include low numbers of OPSCC and ASCC, and lack of 
data on tumor HPV status and behavioral risk factors, including smoking and betel quid 
use. Additionally, some cases had insufficient information to identify a precise tumor site 
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and were classified as ICD-O-3 NOS (“not otherwise specified” tumor site) in the 
Singapore Cancer Registry; thus, misclassification of these cases is another potential 
limitation. Strengths of this study include the use of high-quality cancer registry data that 
is representative of the Singaporean resident population, the long time-interval (>40 
years) included in the analysis, and the Asian ethnic variation explored.  
 
Conclusions 
Our study provides a snapshot of the current burden and recent trends of 
oropharyngeal, anal, cervical and nasopharyngeal cancers in Singapore, a multi-ethnic 
setting where HPV vaccination is not yet widespread. Although HPV-associated cancer 
prevention in Singapore has primarily focused on cervical cancer, our study shows for the 
first time that there is also a burden of potentially HPV-related OPSCC in men, and that 
the incidence is rising, in contrast to non-HPV-related OPSCC and nasopharyngeal 
cancers. Furthermore, our study illustrates differences in burden of these cancers by 
Asian ethnicities, underscoring the need to understand differences in risk factors across 
population subgroups in Singapore’s diverse setting. With progressively increasing 
industrialization and population growth, the epidemiology of these cancers in Singapore 
may reflect the cancer profile we will see in other settings as tobacco cessation efforts 
continue. Understanding the changing epidemiology of HPV-associated cancers is 
important for cancer prevention and provides a picture of cancer risk in a population with 
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n cIR n IR n cIR n cIR n cIR n cIR 
Men 1968-1972 2,608,200 59 2.26 93 3.57 4 0.15 5 0.19 NA NA 547 20.97 
 
1973-1977 3,111,100 59 1.90 110 3.54 9 0.29 8 0.26 NA NA 665 21.38 
 
1978-1982 3,576,850 55 1.54 123 3.44 4 0.11 7 0.20 NA NA 689 19.26 
 
1983-1987 4,108,400 64 1.56 145 3.53 7 0.17 17 0.41 NA NA 861 20.96 
 
1988-1992 4,700,300 74 1.57 135 2.87 8 0.17 23 0.49 NA NA 1,059 22.53 
 
1993-1997 5,276,530 76 1.44 156 2.96 6 0.11 18 0.34 NA NA 1,135 21.51 
 
1998-2002 5,784,960 119 2.06 194 3.35 9 0.16 25 0.43 NA NA 1,108 19.15 
 
2003-2007 6,216,165 139 2.24 181 2.91 11 0.18 49 0.79 NA NA 1,213 19.51 
 
2008-2012 6,871,900 183 2.66 213 3.10 19 0.28 69 1.00 NA NA 1,157 16.84 
 
TOTAL 42,254,405 828 1.96 1,350 3.19 77 0.18 221 0.52 NA NA 8,434 19.96 
Women 1968-1972 2,477,300 4 0.16 39 1.57 4 0.16 4 0.16 603 24.34 216 8.72 
 
1973-1977 3,020,100 4 0.13 34 1.13 5 0.17 7 0.23 676 22.38 266 8.81 
 
1978-1982 3,519,250 15 0.43 53 1.51 12 0.34 2 0.06 751 21.34 322 9.15 
 
1983-1987 4,079,100 10 0.25 56 1.37 10 0.25 11 0.27 896 21.97 371 9.10 
 
1988-1992 4,682,260 14 0.30 68 1.45 9 0.19 11 0.23 998 21.31 440 9.40 
 
1993-1997 5,349,900 15 0.28 84 1.57 6 0.11 25 0.47 1,130 21.12 414 7.74 
 
1998-2002 5,960,376 23 0.39 102 1.71 25 0.42 23 0.39 1,038 17.42 377 6.33 
 
2003-2007 6,480,899 33 0.51 100 1.54 15 0.23 29 0.45 1,014 15.65 414 6.39 
 
2008-2012 7,200,600 52 0.72 132 1.83 20 0.28 35 0.49 913 12.68 373 5.18 
 
TOTAL 42,769,785 170 0.40 668 1.56 106 0.25 147 0.34 8,019 18.75 3,193 7.47 
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All All 85,024,190 998 1.17 2,018 2.37 183 0.22 368 0.43 8,019 18.75 11,627 13.67 
Abbreviations: SCC = squamous cell carcinoma; HNC = head and neck squamous cell carcinoma; ICC = invasive cervical cancer; n = number of cases; 
cIR=crude incidence rate 
1
 Non-age-standardized incidence per 100,000 person-years; 
2
 Only women are included in the person-years denominator when calculating incidence of ICC 
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Table 6-2. Age-standardized incidence rates (ASR) per 100,000 person-years for each cancer, overall and by gender, from 1968 to 
2012 in Singapore 
 
Total Men Women Incidence rate ratio 
(95%CI) 














Oropharyngeal SCC 998 1.38 828 2.44 170 0.44 5.54 (4.69-6.54) 
Non-oropharyngeal HNC 2,018 2.77 1,350 3.91 668 1.74 2.25 (2.05-2.47) 
Anal SCC 183 0.26 77 0.23 106 0.29 0.80 (0.59-1.07) 
Anal non-SCC 368 0.52 221 0.67 147 0.40 1.69 (1.37-2.09) 
Invasive cervical cancer 8,019 19.92 NA NA 8,019 19.92 NA 
Nasopharyngeal 11,627 14.06 8,434 20.63 3,193 7.64 2.70 (2.59-2.81) 
Oropharyngeal  & Anal SCC 1,181 1.64 905 2.67 276 0.73 3.68 (3.21-4.21) 
HPV-associated cancers
2 
9,200 11.83 905 2.67 8,295 20.65 0.13 (0.12-0.14) 
Abbreviations: CI = confidence interval; non-OP HNC = non-oropharyngeal head and neck squamous cell carcinoma; SCC = squamous cell carcinoma 
1 
Age-standardized incidence rates per 100,000 person-years; Age-standardization was done using the direct method and based on the WHO world standard 
population 
2





Table 6-3. Age-standardized incidence rates (ASR) per 100,000 person-years for each cancer, by gender and ethnicity, from 1968 to 



































Oropharyngeal SCC 671 2.53 26 0.72 115 3.64 140 0.44 11 0.31 17 0.96 
Non-oropharyngeal HNC 963 3.56 78 2.03 283 9.12 453 1.42 67 1.67 142 7.51 
Anal SCC  48 0.19 15 0.19 13 0.39 92 0.29 15 0.18 5 0.31 
Anal non-SCC  181 0.70 20 0.55 17 0.57 128 0.41 6 0.41 4 0.20 
Invasive cervical cancer NA NA NA NA NA NA 6,969 21.29 645 14.17 308 13.67 
Nasopharyngeal 7,886 24.78 440 9.54 54 1.53 3,026 9.01 137 2.82 14 0.69 
Oropharyngeal & Anal SCC 719 2.72 41 1.11 128 4.03 232 0.73 26 0.49 22 1.27 
HPV-associated cancers
2 
719 2.72 41 1.11 128 4.03 7,201 22.03 671 14.67 330 14.93 
Abbreviations: non-OP HNC = non-oropharyngeal head and neck squamous cell carcinoma; SCC = squamous cell carcinoma 
1 
Age-standardized incidence rates per 100,000 person-years; Age-standardization was done using the direct method and based on the WHO world standard 
population 
2
 HPV-associated cancers include oropharyngeal SCC, anal SCC and invasive cervical cancer. 
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Table 6-4. Trends in crude and age-standardized invasive cervical cancer incidence (ICC) over time, by ethnicity, from 1968 to 2012 
in Singapore 






















1968-1972 1,992,400 527 26.45 30.80 314,800 45 14.29 18.24 117,200 26 22.18 44.79 
1973-1977 2,421,200 588 24.29 29.46 383,500 43 11.21 13.93 151,800 37 24.37 41.83 
1978-1982 2,826,600 639 22.61 27.98 451,100 49 10.86 15.04 188,700 54 28.62 47.22 
1983-1987 3,262,400 801 24.55 29.37 529,600 56 10.57 14.66 242,500 36 14.85 20.52 
1988-1992 3,733,100 878 23.52 26.90 598,300 82 13.71 18.48 298,170 31 10.40 15.00 
1993-1997 4,266,700 994 23.30 24.94 660,200 90 13.63 16.93 354,800 38 10.71 14.89 
1998-2002 4,736,120 912 19.26 19.17 713,753 79 11.07 11.98 422,463 39 9.23 11.70 
2003-2007 5,080,665 866 17.05 15.76 781,445 104 13.31 14.13 487,817 24 4.92 5.96 
2008-2012 5,529,500 764 13.82 12.23 862,300 97 11.25 11.04 582,400 23 3.95 4.71 
TOTALS 33,848,684 6,969 20.59 21.29 5,294,998 645 12.18 14.17 2,845,850 308 10.82 13.67 
1
 cIR = Crude (non-age standardized) incidence per 100,000 person-years 
2 




Table 6-5. Trends in crude and age-standardized oropharyngeal squamous cell carcinoma (OPSCC) incidence over time, by ethnicity 
and gender, from 1968 to 2012 in Singapore 






















Men 1968-1972 1,946,200 39 2.00 2.82 339,300 3 0.88 1.77 265,400 16 6.03 8.54 
 1973-1977 2,367,600 44 1.86 2.78 406,100 3 0.74 2.16 265,800 11 4.14 5.27 
 1978-1982 2,775,000 40 1.44 2.27 469,900 2 0.43 0.67 276,580 13 4.70 6.70 
 1983-1987 3,210,000 52 1.62 2.47 542,500 1 0.18 0.26 315,600 8 2.53 2.15 
 1988-1992 3,676,900 56 1.52 2.17 611,800 6 0.98 1.86 366,300 12 3.28 3.73 
 1993-1997 4,152,600 63 1.52 1.97 661,600 2 0.30 0.49 408,600 10 2.45 2.52 
 1998-2002 4,544,901 101 2.22 2.71 700,597 5 0.71 1.00 467,146 11 2.35 2.73 
 2003-2007 4,820,243 120 2.49 2.64 756,117 2 0.26 0.19 522,110 14 2.68 3.39 
 2008-2012 5,195,500 156 3.00 2.75 827,400 2 0.24 0.23 642,800 20 3.11 3.81 
 TOTAL 32,688,944 671 2.05 2.53 5,315,314 26 0.49 0.72 3,530,336 115 3.26 3.64 
Women 1968-1972 1,992,400 3 0.15 0.18 314,800 0 0.00 0.00 117,200 1 0.85 5.38 
 1973-1977 2,421,200 4 0.17 0.19 383,500 0 0.00 0.00 151,800 0 0.00 0.00 
 1978-1982 2,826,600 11 0.39 0.48 451,100 1 0.22 0.28 188,700 3 1.59 3.00 
 1983-1987 3,262,400 9 0.28 0.30 529,600 1 0.19 0.25 242,500 0 0.00 0.00 
 1988-1992 3,733,100 11 0.29 0.34 598,300 1 0.17 0.40 298,170 2 0.67 1.65 
 1993-1997 4,266,700 8 0.19 0.21 660,200 3 0.45 0.69 354,800 4 1.13 1.59 
 1998-2002 4,736,120 18 0.38 0.39 713,753 1 0.14 0.12 422,463 2 0.47 0.62 
 2003-2007 5,080,665 29 0.57 0.51 781,445 2 0.26 0.34 487,817 2 0.41 0.65 
 2008-2012 5,529,500 47 0.85 0.71 862,300 2 0.23 0.27 582,400 3 0.52 0.66 
 TOTAL 33,848,685 140 0.41 0.44 5,294,998 11 0.21 0.31 2,845,850 17 0.60 0.96 
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1
 cIR = Crude (non-age standardized) incidence per 100,000 person-years 
2 
ASR = Age-standardized incidence per 100,000 person-years 
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Figure 6-1. Incidence of oropharyngeal and non-oropharyngeal head and neck squamous 




Abbreviations: OPSCC = oropharyngeal squamous cell carcinoma; non-OP HNC = non-oropharyngeal 
head and neck squamous cell carcinoma 
1
 Incidence trends are based on incidence rates for 5-year time periods that were age-adjusted to the WHO 
standard population. Annual percent change (APC) for and are calculated using Joinpoint regression 
analysis. APC = annual percent change. An asterisk (*) indicates an APC value that is statistically 








Abbreviations: SCC = squamous cell carcinoma, non-SCC = non-squamous cell carcinoma 
1
 Incidence trends are based on incidence rates for 5-year time periods that were age-adjusted to the WHO 
standard population and are calculated using Joinpoint regression analysis. APC = annual percent change. 










 Incidence trends are based on incidence rates for 5-year time periods that were age-adjusted to the WHO 
standard population and are calculated using Joinpoint regression analysis. APC = annual percent change. 










 Incidence trends are based on incidence rates for 5-year time periods that were age-adjusted to the WHO 
standard population and are calculated using Joinpoint regression analysis. APC = annual percent change. 










Chapter 7. Dissertation overview and summary of key findings 
 
The purpose of this dissertation research was to investigate risk factors for oral 
HPV persistence and HPV-associated cancers. Epidemiologic and molecular evidence 
strongly link oral HPV infection with oropharyngeal squamous cell carcinoma (OPSCC). 
Persistent oral HPV infection is thought to be a precursor to OPSCC, but unlike HPV 
infection at other anatomic sites, research on oral HPV persistence has been limited. 
Initial evidence suggests that oral HPV natural history may be similar to that of cervical 
HPV, but that there may also be important differences. Additionally, epidemiologic data 
indicate differences in oral HPV and OPSCC incidence and trends by age, biologic sex, 
geography and race/ethnicity. The reasons for these disparities are unclear and research 
has primarily been in Western countries, with limited data from Asian populations.  
The goals of this research were to examine the association of serum cytokines 
(Chapter 3), recreational drug use (Chapter 4) and medication use (Chapter 5) with oral 
HPV clearance. In each of these studies, we focused on HIV-infected individuals and at-
risk HIV-negative individuals, populations with high oral HPV prevalence. To contribute 
Asian data on HPV-associated cancer incidence trends, we described the epidemiology of 
OPSCC and other potentially HPV-associated cancers, and examined population 
subgroups at increased risk in Singapore (Chapter 6).  
In Chapter 3, we presented results of our study on the association of serum 
cytokines (TNF-α, IL-6, IL-8, IFN-γ, IL-1, IL-2, IL-4, IL-10, IL-12 and IL-13) with oral 





knowledge of the cervical HPV model. Select pro-inflammatory cytokines have been 
associated with reduced cervical HPV clearance, but the association of cytokines with 
oral HPV has not been previously investigated. Participants were enrolled in the 
“Persistence of Oral Papillomavirus Study” (POPS), and followed semi-annually. At each 
visit, oral rinse samples were collected for HPV DNA testing and blood samples were 
collected for cytokine testing. We found that while most cytokines were not associated 
with oral HPV clearance, higher concentrations of TNF-, a pro-inflammatory cytokine, 
were associated with reduced clearance of oral HPV infection, and this association 
appeared to be stronger in men than women. This result is consistent with previous 
research which has suggested that higher pro-inflammatory cytokine concentrations, 
particularly TNF-, may be associated with persistent cervical HPV. Furthermore, while 
previous studies restricted the study population to HIV-uninfected participants,
47-49,52
 the 
association between TNF- and clearance in our study remained similar after adjusting 
for HIV infection and CD4 T cell count, suggesting that the relationship between TNF-α 
and oral HPV may be independent of HIV-related immunosuppression. 
In Chapter 4, we present results of a study in the POPS cohort investigating the 
association of recreational drug use with oral HPV clearance. Recreational drugs have 
immunomodulatory effects but their role in oral HPV natural history has not been 
previously explored. We collected semi-annual data on participants’ use of alcohol, 
cigarette, marijuana, crack, cocaine, heroin, amphetamines, ecstasy/club drugs and 
speedball; and in men only, poppers and sexual performance-enhancing drugs. We found 





month time period before first detection of oral HPV infection may be an important risk 
factor for reduced oral HPV clearance.  
In Chapter 5, we present results of a study in the POPS cohort investigating the 
association of medication use with oral HPV clearance. Given the increasing prevalence 
of polypharmacy in the population aging with HIV, and the known immunomodulatory 
effects of several commonly used medications, we undertook this research to evaluate 
whether medication use may affect oral HPV clearance. Data were collected on use of: 
antiasthmatics, antidepressants, antihypertensives, antipsychotics, anxiolytics and 
sedatives, cholesterol-lowering medications, diabetes medications, hormones, non-
steroidal anti-inflammatory drugs (NSAIDs) and erectile dysfunction medications. We 
found that participants using antipsychotic medications had significantly reduced oral 
HPV clearance, and that the effects were stronger in participants with HIV infection. 
Antidepressants and anxiolytics/sedatives were also associated with reduced clearance, 
although the association was not as strong as with antipsychotics. Importantly, combined 
use of 2 or more of these 3 medications (antipsychotics, antidepressants, 
anxiolytics/sedatives) was associated with elevated risk for persisting oral HPV. Each of 
these medications are prescribed for conditions that have immunomodulatory effects, so 
characteristics of the illness may have partially contributed to the reduced oral HPV 
clearance observed in this study.  
Chapter 6 reviews the incidence and temporal trends of potentially HPV-
associated cancers in Singapore. Data from 1968-2012 were compiled from the Singapore 
Cancer Registry, which is representative of the Singapore resident population. We found 





to the burden of cervical cancer among women, but OPSCC incidence was 5 times higher 
in men than women. Ethnic differences in incidence of HPV-associated cancer were 
observed, with higher rates overall among Indian men and among Chinese women than 
other ethnicities. OPSCC rates increased in both men and women in recent years, similar 
to trends reported in other countries of comparable socioeconomic 
status.
2,10,17,18,20,225,226,230-236
 In contrast, the incidence of other head and neck cancers 
(non-oropharyngeal and nasopharyngeal cancer) decreased. Anal cancer was rare. ICC 
was the most common HPV-associated cancer but declined significantly over the 45 
years studied, largely due to the success of Pap screening programs. This research 
suggests the distribution of HPV-associated cancers across population subgroups has 







Chapter 8. Public health implications and  
directions for future research 
 
This dissertation contributes to the scientific literature on HPV-related OPSCC, 
an emerging public health issue in several regions of the globe. The studies presented 
increase our knowledge about immunologic and drug/medication use risk factors that 
may impact oral HPV natural history, and provide insight on risk factors for HPV-
associated cancers. 
To our knowledge, our study of serum cytokines and oral HPV clearance is the 
first to explore the association of circulating immune markers with oral HPV clearance. 
Since there is neither standardized oral screening, nor easily identifiable precursor lesion 
for OPSCC,
63,64
 biomarkers related to infection duration may help identify oral HPV-
infected individuals at increased risk for persistent infection and/or HPV-related OPSCC. 
Future studies, which include longitudinal cytokine evaluation, are needed to clarify the 
role of TNF-α in oral HPV natural history. The results of this study contribute evidence 
that immune differences may explain why some people clear oral HPV while others to do 
not, but questions remain about the role of oral immunity in oral HPV infection. There is 
growing interest in the use of salivary sampling for diagnostic, prognostic and health 
surveillance purposes.
64
 While initial studies suggest that serum cytokine measurements 
correlate with markers detectable in the oral cavity,
82
 the use of these markers as indices 
of oral HPV natural history has not been evaluated. Additional study of immune 





oral HPV and shed useful insight on the role of oral immunity in oral HPV natural 
history.  
This is the first study to report an association of cocaine use with reduced oral 
HPV clearance. Future studies may consider examining whether the frequency and 
intensity of cocaine use affects oral HPV clearance in a dose-response fashion, as we 
were limited in sample size to examine this relationship in our research. The mechanisms 
by which cocaine use may reduce oral HPV clearance is another potential area for 
research. Future studies may consider use of direct measures of cocaine exposure in order 
to reduce biases that could arise from self-reported drug use. Measurement of 
bezoylecgonine, a cocaine metabolite, in oral fluid has been studied for potential use in 
non-clinical contexts, including monitoring of drug use in the workplace, criminal justice 
and point-of-collection testing devices for assessment of driving under the influence.
133
 
However, while bezoylecgonine is the most promising direct measure of cocaine 
exposure, it is metabolized within 1 to 2 days and has relatively low concentrations in 
body fluids.
129,275
 Its use in clinical research of oral HPV may be possible as technologies 
for metabolite detection evolve.
129
   
Immunomodulatory medications may also be a risk factor for oral HPV 
persistence. Our initial results suggest that some medications, particularly those 
prescribed for neuropsychiatric disorders, may reduce oral HPV clearance. However, 
illness characteristics are multi-faceted and complex, as are the treatment regimens 
prescribed to treat them. Additional research on medications subtypes, dosages and 
frequency of usage will be needed to better characterize the relationship between 





Previous studies have suggested that HIV may be associated with reduced oral 
HPV clearance, and so in studying risk factors for oral HPV persistence, we considered 
each potential risk factor separately by HIV status. While there was some suggestion that 
the effects of cocaine and antipsychotic medication on reduced oral HPV clearance were 
stronger in HIV-infected individuals as compared to HIV-uninfected individuals, we 
found no compelling evidence that HIV substantially modified the effects of these 
potential risk factors. As it is difficult to disentangle the influences of HIV-related 
immunodeficiency and ongoing immune dysfunction, from the immunomodulatory 
effects of other exposures, it remains important in future research to examine potential 
effect modification by HIV status.  
The analysis of cancer epidemiology in Singapore increases our understanding of 
the current burden and trends of HPV-associated cancers, contributing some of the first 
Asian data on this topic. Although HPV-associated cancer prevention in Singapore has 
primarily focused on cervical cancer, our study shows for the first time that there is also a 
burden of potentially HPV-related OPSCC in men, and that the incidence is rising, in 
contrast to other head and neck cancers. Initial research suggests HPV vaccination will 
likely also be effective in preventing oral HPV infection and thus could impact OPSCC 
rates.
267,268
 Current HPV prevention efforts in Singapore focus primarily on cervical 
cancer, but should prevention efforts expand to include HPV-related OPSCC, it will be 
important to monitor changes from the baseline epidemiologic profile we report in our 
study. The 45-year period that we studied encompassed Singapore’s rapid transition from 
a low-income to a high-income country. This economic transition was accompanied by 







 The incidence and trends of the cancers we describe during 
Singapore’s economic transition may be relevant for the future cancer patterns in other 
economically rising countries in Asia. Patients with HPV-associated HNSCC have better 
survival and treatment outcomes than patients with HPV-negative HNSCC,
1
 and thus, 
shifts in HNSCC mortality may also be observed along with the changing etiologic 
profile of these cancers.  
Our study is one of the first investigations of disparities in HPV-associated cancer 
incidence in the major ethnic groups in Singapore (ie. Chinese, Malay, Indian). The 
results of the research may be useful to inform cancer prevention strategies for 
Singaporean subgroups at highest risk for HPV-associated cancers. In order to develop 
appropriate public health prevention programs and interventions, future research 
exploring the underlying reasons for disparities in cancer incidence and trends will be 
important. Currently, HPV tumor typing is not routinely done in Singapore and so we 
could not confirm the contribution of HPV infection to the incidence and trends observed. 
Future studies, which include HPV tumor status, may be able to more clearly distinguish 
tobacco/alcohol- vs. HPV-related OPSCC, especially if trends in these etiologically 
distinct cancers continue to diverge.  
The findings presented in this dissertation contribute to explaining why the 
burden of OPSCC and other HPV-associated cancers are disproportionately high in some 
population subgroups. We have presented new insights on immunologic and 
drug/medication use factors that may influence oral HPV persistence and have uncovered 





these initial findings may help shape cancer prevention strategies in HIV-infected 





Appendix A. Conceptual framework for factors associated with oral HPV persistence 






Appendix B. MACS drug use questionnaire 
 
[Modified from MACS Follow-up Visit form, Section 4] 
 
I am going to ask you a series of questions about specific behaviors, including cigarette 
smoking, alcohol use, sexual behavior, and recreational drug use. 
 
Now I have some questions about cigarette smoking.  
 
Have you ever smoked cigarettes? 
o No 
o Yes 
Do you smoke cigarettes now? (As of one month ago)? 
o No 
o Yes 
o Occasionally (less than one cigarette per day) 
 
How many packs do you usually smoke per day? 
o Less than ½ pack 
o At least ½ pack, but less than one pack per day 
o At least 1 but less than 2 packs 
o 2 or more packs per day 
 
The next set of questions are about alcoholic beverages. They may seem similar, but they 
are asked in a slightly different way. 
Please answer each of the following questions for the past 6 months. 
 
How often have you had drinks containing alcohol? 
o Never 
o Less than monthly 
o Monthly 
o Weekly 
o Daily or almost daily 
 
During the past 6 months, how many drinks containing alcohol have you had on a typical 
day when you are drinking? (A “drink” is defined as one 12-ounce beer, one 5-ounce 
glass of wine, or one mixed drink with 1 and 1/2 ounces of 80-proof hard liquor.)  
o None 
o 1 or 2 
o 3 or 4 
o 5 or 6 
o 7 to 9 






During the past 6 months, how often have you had six or more drinks on one occasion? 
(A “drink” is defined as one 12-ounce beer, one 5-ounce glass of wine, or one mixed 
drink with 1 and 1/2 ounces of 80-proof hard liquor.)  
o Never 
o Less than monthly 
o Monthly 
o Weekly 
o Daily or almost daily 
 
Now let’s talk about other drugs you may have used. As I read each one, please tell me 
whether you used it even once since your last visit [in (MONTH, YEAR)]? 
How about (EACH) Have you (taken/used) any since your last visit [in (MONTH, 
YEAR)]? 
 
1. Pot, marijuana or hash 
2. “Poppers” like nitrite inhalants (amyl, butyl or isopropyl nitrites) 
3. Crack or cocaine that you smoke 
4. Other forms of cocaine 
5. Speed, meth or ice 
6. Heroin 
7. Speedball (heroin and cocaine together) 
8. Ecstasy, XTC, X or MDMA 
9. Sexual performance enhancing drugs other than those prescribed by a medical 
provider for diagnosed erectile dysfunction (Show list of performance enhancing 
drugs to prompt and assist with recall) 
10. Other kinds of street/club drugs 
 




o Less often 
 




o Put in anus (“booty bumped”) 
o Smoked 






Appendix C. WIHS drug use questionnaire 
 
[Modified from WIHS “F24Beh: Alcohol, drug use and sexual behavior” interviewer 
script and questionnaire] 
 
Now I am going to ask you some personal questions about your cigarette and alcohol use, 
if any. 
 




How many cigarettes, on the average, do you smoke each day? 
 
 
Since your (MONTH) study visit, did you drink beer, wine, hard liquor or any other 




Now I’m going to ask you about the alcoholic beverages you drank since your (MONTH) 
study visit. By “a drink” I mean one can, bottle or glass of beer, a glass of wine, a shot of 
liquor, a mixed drink with that amount of liquor, or any other alcoholic beverage. 
 
a. Since your (MONTH) study visit, how often did you have a drink containing 
alcohol?    
o 1-2 days a week  
o 1-2 times a month 
o About once a month  
o 6-11 times a year  
o 1-5 times a year  
 
b. Since your (MONTH) study visit, on a day when you drank any alcoholic 
beverages, about how many did you USUALLY have altogether?    
o 1 drink  
o 2 drinks 
o 3 drinks 
o 4 drinks 
o 5 drinks 
o 6 drinks 
o 7 to 9 drinks 






Now I will ask you a few questions about drug use. Your answers are strictly 
confidential. 
 
Since your (MONTH) study visit, have you used marijuana, either medical or 
recreational, cocaine, crack, heroin, methamphetamine, hallucinogens, club drugs, or any 
other illicit or recreational drugs? If yes, continue with questionnaire. 
 
Since your (MONTH) study visit, have you used marijuana or hash to get high, for 
medical reasons, or both? 
 
On average, how often did you use marijuana or hash recreationally since your 
(MONTH) study visit? 
o Less than once a month  
o At least once a month, but less than once a week  
o Once a week  
o 2 – 3 times a  
o 4 – 6 times a week  
o Once a day  
o More than once a day  
o Never 
 
(Since your (MONTH) study visit), have you smoked crack? 
On average, how often have you smoked crack since your (MONTH) study visit? 
o Less than once a month  
o At least once a month, but less than once a week  
o Once a week  
o 2 – 3 times a week  
o 4 – 6 times a week  
o Once a day  
o More than once a day  
 
(Since your (MONTH) study visit), have you injected crack by itself? 
 
On average, how often have you injected crack since your (MONTH) study visit? 
o Less than once a month  
o At least once a month, but less than once a week  
o Once a week  
o 2 – 3 times a week  
o 4 – 6 times a week  
o Once a day  
o More than once a day  
 
(Since your (MONTH) study visit), have you sniffed, snorted, or smoked cocaine? 
On average, how often have you sniffed, snorted, or smoked cocaine since your 
(MONTH) study visit? 





o At least once a month, but less than once a week  
o Once a week  
o 2 – 3 times a week  
o 4 – 6 times a week  
o Once a day  
o More than once a day  
 
(Since your (MONTH) study visit), have you injected cocaine by itself? 
 
On average, how often have you injected cocaine since your (MONTH) study visit? 
o Less than once a month  
o At least once a month, but less than once a week  
o Once a week  
o 2 – 3 times a week  
o 4 – 6 times a week  
o Once a day  
o More than once a day  
 
(Since your (MONTH) study visit), have you sniffed or snorted heroin? 
 
On average, how often have you sniffed or snorted heroin since your (MONTH) study 
visit? 
o Less than once a month  
o At least once a month, but less than once a week  
o Once a week  
o 2 – 3 times a week  
o 4 – 6 times a week  
o Once a day  
o More than once a day  
 
(Since your (MONTH) study visit), have you smoked heroin? 
 
On average, how often have you smoked heroin since your (MONTH) study visit? 
o Less than once a month  
o At least once a month, but less than once a week  
o Once a week  
o 2 – 3 times a week  
o 4 – 6 times a week  
o Once a day  
o More than once a day  
 
(Since your (MONTH) study visit), have you injected heroin by itself? 
 
On average, how often have you injected heroin since your (MONTH) study visit? 
o Less than once a month  





o Once a week  
o 2 – 3 times a week  
o 4 – 6 times a week  
o Once a day  
o More than once a day  
 
(Since your (MONTH) study visit), have you injected heroin and cocaine together 
(speedball)? 
 
On average, how often have you injected heroin and cocaine together (speedball) since 
your (MONTH) study visit? 
o Less than once a month  
o At least once a month, but less than once a week  
o Once a week  
o 2 – 3 times a week  
o 4 – 6 times a week  
o Once a day  
o More than once a day  
 
(Since your (MONTH) study visit), have you sniffed or smoked methamphetamine 
(crank, crystal, tina)? 
 
On average, how often have you sniffed or smoked methamphetamine since your 
(MONTH) study visit? 
o Less than once a month  
o At least once a month, but less than once a week  
o Once a week  
o 2 – 3 times a week  
o 4 – 6 times a week  
o Once a day  
o More than once a day  
 
(Since your (MONTH) study visit), have you injected methamphetamine (crank, 
crystal, tina) by itself? 
 
On average, how often have you injected methamphetamine since your (MONTH) study 
visit? 
o Less than once a month  
o At least once a month, but less than once a week  
o Once a week  
o 2 – 3 times a week  
o 4 – 6 times a week  
o Once a day  










(Since your (MONTH) study visit), have you used any club drugs, such as ecstasy, 
ketamine or GHB? 
 
On average, how often have you used club drugs since your (MONTH) study visit? 
o At least once a month, but less than once a week  
o Once a week  
o 2 – 3 times a week  
o 4 – 6 times a week  
o Once a day  
o More than once a day  
 
 
(Since your (MONTH) study visit), have you used amphetamines (speed, uppers) in a 
way that was not prescribed? Not prescribed means you didn’t have a doctor’s 
prescription for the amphetamine, you used more than was prescribed, or you used it to 
get high. 
 
On average, how often have you used amphetamines in a way that was not prescribed 
since your (MONTH) study visit? 
 
o Less than once a month  
o At least once a month, but less than once a week  
o Once a week  
o 2 – 3 times a week  
o 4 – 6 times a week  
o Once a day  






Appendix D. MACS medication use questionnaire 
 
[Modified from MACS Follow-up Visit form, Section 4] 
 
 
Now, I have some questions about drugs and medications that you may have taken for 
other health reasons. These include prescribed medications, over the counter medications, 
and other medications you took on your own since your last visit [in (MONTH, YEAR)]. 
 
How about [EACH]? Have you (taken/used) any since your last visit [in (MONTH, 
YEAR)]? 
 
1. Steroids that you took by mouth or were injected 
2. Thyroid hormone or thyroid medication 
3. Other hormones such as anabolic steoroids 
4. Tranquilizers or sleeping pills 
5. Antidepressants or mood elevators 
6. Lithium 
7. Viagra, Cialis, Levitra or other drugs that were prescribed by a medical provider 
to treat erectile dysfunction 
8. Aspirin taken three days or more on a weekly basis 
9. Medications to lower cholesterol, triglycerides, lipids or blood fat 
10. Medications to treat hypertension 
11. Medications to treat diabetes 
 
Have you (taken/used) any other medications since your last visit [in (MONTH, 
YEAR)]? 
When specified, what was the name of the (KIND OF DRUG) you took?  






Appendix E. WIHS medication use questionnaire 
 
[Modified from Form 22 Med: Medication History] 
 
How I am going to ask you a series of questions about medicines that you may have had 
or taken since your study visit on MM/DD/YY. 
 
Also, if at any point in the interview you wish to stop, let me know. 
 
Finally, I need to re-emphasize that all your answers are confidential, and the responses 
you provide will in no way affect your clinical care. 
 
Since your (MONTH) study visit, have you taken any of the following hormone 
replacement therapies (hormones, estrogen, progesterone) for more than one month? 
These therapies could have been taken in the form of a pill, cream, or patch worn on the 
skin. Please do not include any hormones taken only to prevent pregnancy; we will 
discuss those later in the interview. 
 
ESTROGEN: Premarin, Estrace, Estratab, Menest, Ogen, Cenestin, Estraderm, Climara, 
Menostar, Estrasorb, Alora, Enjuvia, Evamist, Femring, Vivelle-Dot 
 
PROGESTERONE: Provera, Cycrin, Amen, Prometrium, Micronor, Nor-QD 
 
COMBINATION ESTROGEN/PROGESTERONE: Premphase, Prempro, Combipatch, 
Angeliq, Activella, Prefest 
 
OTHER HRT: Tamoxifen, Raloxifene, testosterone patch or cream, Estratest 
(combination estrogen/testosterone), birth control pills, Norplant, Ortho Evra (birth 





Since your (MONTH) study visit, have you taken any medication for blood pressure or 





(Since your (MONTH) study visit), have you taken any medication to lower your 








(Since your (MONTH) study visit), have you taken any medication to lower your blood 




(Since your (MONTH) study visit), have you taken any medication for psychological 




(Since your (MONTH) study visit), have you taken any medication for HIV 




(Since your (MONTH) study visit), have you taken any medication for breathing or lung 
problems,(such as Singulair, monteleukast, Accolate, zafirlukast, Zyflo, zileutin, 












Appendix F. Medication types and classification 
 
Medication type Medication class(es) 
Examples of medication brand names 




2. Leukotriene modifiers 
1. Ventolin (albuterol), Xopenex (levalbuterol), 
Servent (salmeterol) 
2. Singulair (montelukast), Accolate (zafirlukast) 
Antiasthmatic (steroidal) 
Inhaled steroids Advair (fluticasone+salmeterol), Flovent (fluticasone), 
Symbicort (budesonide with formoterol), Aerobid 
(flunisolide), Azmacort (triamcinolone) 
Antidepressants 
1. Selective serotonin reuptake 
inhibitors (SSRIs) 
2. Serotonin-norepinephrine reuptake 
inhibitors (SNRIs) 
3. Norepinephrine reuptake inhibitors 
(NRIs) 
1. Celexa (citalopram), Paxil (paroxetine), Zoloft 
(sertraline), Prozac (fluoxetine) 
2. Cymbalta (duloxetine) 




3. Beta-blocking agents 
4. Calcium channel blockers 
5. Other, including anti-adrenergic 
agents  
1. Microzide (hydrochlorothiazide), Lasix 
(furosemide), acetazolamide 
2. Vasotec (enalapril), Prinivil (eisinopril), verapamil 
3. Lopressor (metoprolol), Coreg (carvedilol), 
Tenormin (atenolol) 
4. Procardia (nifedipine), Norvasc (amlodipine) 
5. Nexiclon (clonidine), hydralazine 
Antipsychotics 
1. Typical 
2. Atypical  
1. Abilify (aripiprazole), Haldol (haloperidol), lithium 
2. Risperdal (risperidone), Seroquel (quetiapine)  
Anxiolytics/sedatives 
1. Benzodiazepines 
2. Other sedatives 
1. Xanax (alprazolam), Valium (diazepam), Ativan 









Lipitor (atorvastatin), Altocor, Altoprev, Mevacor (all 
lovastatin), Tricor (fenofibrate), Crestor (rosuvastatin), 
Pravigard   (pravastatin), Vytorin 
(ezetimibe+simvastatin) 
Diabetes 
1. Insulin and analogues 
2. Blood glucose lowering drugs, 
excluding insulins 
3. Other drugs used in diabetes, 
including combination drugs 
 
1. Lantus (glargine), Apidra (insulin glulisine) 
2. Januvia (sitagliptin), Glucophage (metformin), 
Glucotrol (glipizide), Diabeta (mlyburide), Glyset 
(Migitol), Actos (pioglitazone) 
3. Janumet (sitagliptin+metformin), Glucovance 
(Glyburide+ Metformin) 
Erectile dysfunction (men only) 
PDE 5 inhibitors Viagra (sildenafil), Cialis (tadalafil), Levitra 
(vardenafil) 
Hormones 
 Levothyroid (levothyroxine), Cytomel (liothyronine), 
growth hormone, estrogen, testosterone 
Non-steroidal anti-
inflammatory drugs (NSAIDs) 
Anti-inflammatory Advil (ibuprofen), Aleve (naproxen), aspirin, 
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